

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



Evans, JR; Lawrenson, JG (2012) Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. The Cochrane database of systematic reviews, 6. CD000253. ISSN 1469-493X DOI: <https://doi.org/10.1002/14651858.CD000253.pub3>

Downloaded from: <http://researchonline.lshtm.ac.uk/21097/>

DOI: [10.1002/14651858.CD000253.pub3](https://doi.org/10.1002/14651858.CD000253.pub3)

#### Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: Copyright the publishers



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration (Review)

Evans JR, Lawrenson JG

Evans JR, Lawrenson JG.

Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.

*Cochrane Database of Systematic Reviews* 2012, Issue 6. Art. No.: CD000253.

DOI: 10.1002/14651858.CD000253.pub3.

[www.cochranelibrary.com](http://www.cochranelibrary.com)

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . .	3
BACKGROUND . . . . .	4
OBJECTIVES . . . . .	4
METHODS . . . . .	4
RESULTS . . . . .	6
Figure 1. . . . .	7
Figure 2. . . . .	8
ADDITIONAL SUMMARY OF FINDINGS . . . . .	9
DISCUSSION . . . . .	11
AUTHORS' CONCLUSIONS . . . . .	11
ACKNOWLEDGEMENTS . . . . .	12
REFERENCES . . . . .	12
CHARACTERISTICS OF STUDIES . . . . .	20
DATA AND ANALYSES . . . . .	37
Analysis 1.1. Comparison 1 Any antioxidant versus placebo, Outcome 1 AMD. . . . .	38
Analysis 1.2. Comparison 1 Any antioxidant versus placebo, Outcome 2 Advanced AMD. . . . .	39
Analysis 2.1. Comparison 2 Alpha-tocopherol versus placebo, Outcome 1 AMD. . . . .	40
Analysis 2.2. Comparison 2 Alpha-tocopherol versus placebo, Outcome 2 Advanced AMD. . . . .	40
Analysis 3.1. Comparison 3 Beta-carotene versus placebo, Outcome 1 AMD. . . . .	41
Analysis 3.2. Comparison 3 Beta-carotene versus placebo, Outcome 2 Advanced AMD. . . . .	42
APPENDICES . . . . .	42
WHAT'S NEW . . . . .	47
HISTORY . . . . .	48
CONTRIBUTIONS OF AUTHORS . . . . .	48
DECLARATIONS OF INTEREST . . . . .	48
SOURCES OF SUPPORT . . . . .	49
INDEX TERMS . . . . .	49

[Intervention Review]

# Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration

Jennifer R Evans<sup>1</sup>, John G Lawrenson<sup>2</sup>

<sup>1</sup>Cochrane Eyes and Vision Group, ICEH, London School of Hygiene & Tropical Medicine, London, UK. <sup>2</sup>Division of Optometry & Visual Science, City University, London, UK

Contact address: Jennifer R Evans, Cochrane Eyes and Vision Group, ICEH, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. [jennifer.evans@lshtm.ac.uk](mailto:jennifer.evans@lshtm.ac.uk).

**Editorial group:** Cochrane Eyes and Vision Group.

**Publication status and date:** New search for studies and content updated (no change to conclusions), published in Issue 6, 2012.

**Citation:** Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. *Cochrane Database of Systematic Reviews* 2012, Issue 6. Art. No.: CD000253. DOI: 10.1002/14651858.CD000253.pub3.

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

There is inconclusive evidence from observational studies to suggest that people who eat a diet rich in antioxidant vitamins (carotenoids, vitamins C and E) or minerals (selenium and zinc) may be less likely to develop age-related macular degeneration (AMD).

### Objectives

To examine the evidence as to whether or not taking antioxidant vitamin or mineral supplements prevents the development of AMD.

### Search methods

We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (*The Cochrane Library* 2011, Issue 12), MEDLINE (January 1950 to January 2012), EMBASE (January 1980 to January 2012), Open Grey (System for Information on Grey Literature in Europe) ([www.opengrey.eu/](http://www.opengrey.eu/)), the metaRegister of Controlled Trials (mRCT) ([www.controlled-trials.com](http://www.controlled-trials.com)), ClinicalTrials.gov ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)) and the WHO International Clinical Trials Registry Platform (ICTRP) ([www.who.int/ictrp/search/en](http://www.who.int/ictrp/search/en)). There were no date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 26 January 2012.

### Selection criteria

We included all randomised controlled trials (RCTs) comparing an antioxidant vitamin and/or mineral supplement (alone or in combination) to control.

### Data collection and analysis

Both review authors independently assessed risk of bias in the included studies and extracted data. One author entered data into RevMan 5 and the other author checked the data entry. We pooled data using a fixed-effect model.

### Main results

We included four RCTs in this review; 62,520 people were included in the analyses. The trials were conducted in Australia, Finland and the USA and investigated vitamin E and beta-carotene supplements. Overall the quality of the evidence was high. People who took these supplements were not at decreased (or increased) risk of developing AMD. The pooled risk ratio for any antioxidant supplement in the prevention of any AMD was 0.98 (95% confidence interval 0.89 to 1.08) and for advanced AMD was 1.05 (95% CI 0.80 to 1.39). Similar results were seen when the analyses were restricted to beta-carotene and alpha-tocopherol alone.

### **Authors' conclusions**

There is accumulating evidence that taking vitamin E or beta-carotene supplements will not prevent or delay the onset of AMD. There is no evidence with respect to other antioxidant supplements, such as vitamin C, lutein and zeaxanthin, or any of the commonly marketed multivitamin combinations. Although generally regarded as safe, vitamin supplements may have harmful effects and clear evidence of benefit is needed before they can be recommended. People with AMD should see the related Cochrane review 'Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration' written by the same review team.

## **PLAIN LANGUAGE SUMMARY**

### **Antioxidant vitamins and mineral supplements to prevent the development of age-related macular degeneration**

Age-related macular degeneration (AMD) is a condition affecting the central area of the retina (back of the eye). The retina can deteriorate with age and some people get lesions that can lead to loss of central vision. Some studies have suggested that people who eat a diet rich in antioxidant vitamins (carotenoids, vitamins C and E) or minerals (selenium and zinc) may be less likely to get AMD. The authors identified four large, high-quality randomised controlled trials which included 62,520 people. The trials were conducted in Australia, Finland and the USA and investigated the effects of vitamin E and beta-carotene supplementation. These trials provide evidence that taking vitamin E and beta-carotene supplements is unlikely to prevent the onset of AMD. There was no evidence for other antioxidant supplements and commonly marketed combinations. Although generally regarded as safe, vitamin supplements may have harmful effects and clear evidence of benefit is needed before they can be recommended.

## SUMMARY OF FINDINGS FOR THE MAIN COMPARISON [\[Explanation\]](#)

Antioxidant supplement compared with placebo for prevention of AMD						
Patient or population: general population Settings: community Intervention: vitamin E Comparison: placebo						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Placebo	Antioxidant supplementation				
Any AMD	180 per 1000	181 per 1000 (159 to 204)	RR 0.97 (0.85 to 1.09)	40,887 (4)	⊕⊕⊕⊕ high	
Advanced AMD	6 per 1000	8 per 1000 (5 to 13)	RR 1.34 (0.84 to 2.14)	40,887 (4)	⊕⊕⊕⊕ high	

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  
**AMD**: age-related macular degeneration; **CI**: confidence interval; **RR**: risk ratio

GRADE Working Group grades of evidence  
**High quality**: Further research is very unlikely to change our confidence in the estimate of effect.  
**Moderate quality**: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  
**Low quality**: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  
**Very low quality**: We are very uncertain about the estimate.

## BACKGROUND

### Description of the condition

Age-related macular degeneration (AMD) is a disease affecting the central area of the retina (macula). In the early stages of the disease lipid material accumulates in deposits underneath the retinal pigment epithelium. These deposits are known as drusen, and can be seen as pale yellow spots on the retina. The pigment of the retinal pigment epithelium may become disturbed, with areas of hyperpigmentation and hypopigmentation. In the later stages of the disease, the retinal pigment epithelium may atrophy completely. This loss can occur in small focal areas or can be widespread (geographic). In some cases, new blood vessels grow under the retinal pigment epithelium and occasionally into the subretinal space (exudative or neovascular). Haemorrhage can occur which often results in increased scarring of the retina.

The early stages of the disease are in general asymptomatic. In the later stages there may be considerable distortion within the central visual field leading to a complete loss of central visual function. Population-based studies suggest that, in people 65 years and older, approximately 5% have advanced AMD (Owen 2012). It is the most common cause of blindness and visual impairment in industrialised countries. In the UK for example, over 30,000 people are registered as blind or partially sighted annually, half of whom have lost their vision due to macular degeneration (Bunce 2006).

### Description of the intervention

Photoreceptors in the retina are subject to oxidative stress throughout life due to combined exposures to light and oxygen. It has been proposed that antioxidants may prevent cellular damage in the retina by reacting with free radicals produced in the process of light absorption (Christen 1996).

There are a number of non-experimental studies that have examined the possible association between antioxidant micronutrients and AMD, although few studies have examined supplementation specifically (Chong 2007; Evans 2001). Data on vitamin intake in observational studies should be considered cautiously as people who have a diet rich in antioxidant vitamins and minerals, or who choose to take supplements regularly, are different in many ways from those who do not; these differences may not be adequately controlled by statistical analysis. The results of these observational studies have been inconclusive.

### How the intervention might work

The underlying theory is that antioxidant vitamin and mineral supplements will protect the retina against oxidative stress and that this protection will delay the onset of AMD.

### Why it is important to do this review

Antioxidant vitamin and mineral supplements are increasingly being marketed for use in age-related eye disease, including AMD. The aim of this review was to examine the evidence as to whether or not taking vitamin or mineral supplements prevents the development of AMD. See also the related Cochrane review 'Antioxidant vitamin and mineral supplements for slowing the progression of AMD' which considers whether supplementation for people with AMD slows down the progression of the disease (Evans 2006).

## OBJECTIVES

To determine whether antioxidant vitamin and/or mineral supplementation prevents the development of AMD.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

We included randomised controlled trials (RCTs) comparing antioxidant vitamin and/or mineral supplementation (alone or in combination) to control.

#### Types of participants

Participants in the trials were people in the general population, with or without diseases other than AMD. We excluded trials in which the participants were exclusively people with AMD. These trials are considered in a separate Cochrane review examining the effect of supplementation on progression of the disease (Evans 2006).

#### Types of interventions

Antioxidants were defined as any vitamin or mineral which is known to have antioxidant properties *in vivo* or which is known to be an important component of an antioxidant enzyme present in the retina. We considered the following: vitamin C, vitamin E, carotenoids (including the macula pigment carotenoids lutein and zeaxanthin), selenium and zinc.

#### Types of outcome measures

The following outcomes were used:

1. number of participants developing AMD;
2. number of participants with visual loss due to AMD;
3. quality of life measures;

4. any adverse outcomes reported.

We used the following definitions:

AMD: this was taken as defined by trial investigators. It is commonly defined as: in the macular area 3000 microns diameter from fovea: drusen with or without pigmentary abnormalities or geographic atrophy or characteristic choroidal neovascularisation with no other cause. Where possible, we have used the Age-Related Eye Disease Study System for classifying age-related macular degeneration (AREDS 2001b). In particular, the term 'advanced AMD' refers to geographic atrophy or neovascular AMD.

Visual loss: any well-defined outcome based on visual acuity was used depending on the way in which authors presented trial data.

Quality of life: any validated measurement scale which aims to measure the impact of visual function loss on quality of life of participants.

## Search methods for identification of studies

### Electronic searches

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2011, Issue 12, part of *The Cochrane Library*. [www.thecochranelibrary.com](http://www.thecochranelibrary.com) (accessed 26 January 2012), MEDLINE (January 1950 to January 2012), EMBASE (January 1980 to January 2012), Open Grey (System for Information on Grey Literature in Europe) ([www.opengrey.eu/](http://www.opengrey.eu/)), the metaRegister of Controlled Trials (mRCT) ([www.controlled-trials.com](http://www.controlled-trials.com)), ClinicalTrials.gov ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)) and the WHO International Clinical Trials Registry Platform (ICTRP) ([www.who.int/ictrp/search/en](http://www.who.int/ictrp/search/en)). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 26 January 2012.

See: Appendices for details of search strategies for CENTRAL (Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix 3), Open Grey (Appendix 5), mRCT (Appendix 6), ClinicalTrials.gov (Appendix 7) and the ICTRP (Appendix 8).

For the update in 2012 we specifically looked for adverse effects using a simple search aimed to identify systematic reviews of adverse effects of vitamin supplements, see Appendix (Appendix 9) for search strategy.

### Searching other resources

We searched the Science Citation Index and the reference lists of reports of trials that were selected for inclusion. We contacted the investigators of included and excluded trials to ask if they knew of any other relevant published or unpublished trials.

## Data collection and analysis

## Selection of studies

Our initial searches identified all trials of antioxidant supplements and therefore generated many citations. Each review author assessed half of the titles and abstracts resulting from the searches and selected studies according to the definitions in the '[Criteria for considering studies for this review](#)'. To check that we were consistent, we both assessed a subset of 100 records and compared results. We obtained full copies of all reports referring to controlled trials that definitely or potentially met the inclusion criteria. We assessed the full copies and selected studies according to the inclusion criteria. We wrote to authors of trials for which there were no published outcome data on AMD to ask whether they had collected any data on eye disease outcomes.

As none of the trials responded positively, i.e. gave us unpublished data on AMD, for further updates of this review we only considered trials with published data on AMD.

In updates to this review, both authors went through the titles and abstracts resulting from the searches independently and resolved disagreements by discussion.

## Data extraction and management

We extracted data using methods forms developed by the Cochrane Eyes and Vision Group (<http://eyes.cochrane.org/resources-review-authors>). We extracted data independently and resolved disagreements by discussion. One author cut and pasted the data into RevMan 5 (Review Manager 2011) and the other author checked that this had been done correctly.

## Assessment of risk of bias in included studies

Two authors independently assessed risk of bias using the Cochrane Collaboration's tool for assessing risk of bias as described in Chapter 8 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). We resolved disagreements by discussion. We contacted trial authors for clarification on any parameter graded as 'unclear'. The review authors were not masked to any trial details.

## Measures of treatment effect

Our measure of treatment effect was the risk ratio for dichotomous outcomes and the mean difference for continuous outcomes. Currently the review only includes analysis of dichotomous outcomes.

## Unit of analysis issues

The interventions, by definition, are applied to the person but as most people have two eyes trials can analyse data from one or both eyes. The trials included in this review reported the development of AMD in either eye of the person therefore the unit of analysis was the same as the unit of randomisation.



### Assessment of heterogeneity

We assessed heterogeneity by visual inspection of the forest plot, the  $\chi^2$  test for heterogeneity and the  $I^2$  statistic.

### Data synthesis

We summarised data using the risk ratio, after testing for heterogeneity between trial results using a standard  $\text{Chi}^2$  test.

### Subgroup analysis and investigation of heterogeneity

No subgroup analyses were planned. Only four trials are included at present which means that it is not possible to investigate heterogeneity formally.

### Sensitivity analysis

We planned to conduct sensitivity analyses to determine the impact of study quality on effect size. Currently there are four high-quality trials included in the review and therefore this is not relevant at present.

## RESULTS

### Description of studies

#### Results of the search

The initial searches resulted in 3178 titles and abstracts. Of these, 208 were reports of potentially eligible trial reports. From these reports we identified seven primary prevention trials of antioxidant vitamin or mineral supplements (ATBC 1994; CARET; de Klerk 1998; LINXIAN; Nambour 1995; PHS I; WHS). Investigators from three trials have confirmed that they did not collect data on AMD (CARET; de Klerk 1998; Nambour 1995). These trials have been excluded from the review. We did not receive a response from one trial (LINXIAN) and this trial has been excluded. Three trials have published data on AMD outcomes (ATBC 1994; PHS I; WHS) and are included in this review. Search of the National Eye Institute Clinical Research register identified one further ongoing trial which is collecting information on AMD - the Women's Antioxidant Cardiovascular Study (WACS). There are two trials that have recruited participants with and without AMD (AREDS; VECAT). VECAT is included in this review because 82% of participants did not have signs of AMD. AREDS is not included in this review because AMD outcomes for people without AMD at baseline were not reported; it is included in the Cochrane review examining the effect of supplementation on progression of the disease (Evans 2006).

The original search strategy involved identifying all trials of antioxidant interventions and asking trialists if they had collected data on AMD. We wrote to the authors of 60 trials of antioxidant interventions in people with diseases other than AMD. We received 15 responses and none had collected any relevant data. All 60 trials are shown in the excluded studies section of this review. As this proved to be an inefficient way of identifying relevant trials, subsequent searches included terms for AMD. Three hundred and sixty-seven reports of trials were found in May 2002, 343 in May 2005 and 64 reports in January 2006 but no further trials were identified that were relevant for inclusion in this review. The results of the PHS I study were published in 2007. The searches were repeated in August 2007 in which a total of 129 reports of studies were identified. The Trials Search Co-ordinator (TSC) scanned the search results and removed 84 references which were not relevant to the scope of the review. We screened the title and abstracts of the remaining 45 references and obtained full-text copies of four reports to assess for potential inclusion in the review. We identified one new report from the PHS I study to be included in the review and the three remaining studies were excluded. For reasons of exclusion, see 'Characteristics of excluded studies' table. An update search was done in January 2012 which yielded 477 titles and abstracts. The TSC scanned the search results and removed 206 references which were not relevant to the scope of the review. We screened the title and abstracts of the remaining 271 references. We rejected 267 abstracts as not eligible for inclusion in the review. We obtained full-text copies of four reports for further examination. One new report from the WHS study has been included in the review and three other studies were excluded. For reasons of exclusion, see 'Characteristics of excluded studies' table.

#### Included studies

See the 'Characteristics of included studies' table for more detailed information.

#### Types of participants

The studies took place in Australia, USA and Finland. Two studies recruited men only (ATBC 1994; PHS I), one study recruited women only (WHS) and one study recruited men and women (VECAT). People taking part in the trials were identified from the general population. Participants in PHS I were male physicians and in WHS were female health professionals. In ATBC 1994, a random sample of 1035 men aged 65 years or above from the main study were invited to participate with a response rate of 91% (941 men). In VECAT, 18% had AMD at baseline.

#### Types of intervention

In ATBC 1994, the groups received either alpha-tocopherol 50 mg per day alone, beta-carotene 20 mg per day alone, alpha-tocopherol and beta-carotene or placebo. All formulations were

coloured with quinoline yellow. Treatment duration was five to eight years (median 6.1 years). In [VECAT](#), participants were randomised to vitamin E (500 IU a day) or placebo. Supplementation continued for four years. In [PHS I](#), the groups received aspirin 325 mg every other day, beta-carotene 50 mg every other day, aspirin and beta-carotene or placebo. Treatment duration averaged 12 years. In [WHS](#), participants received vitamin E (600 IU on alternate days) or placebo and were followed up for 10 years.

### Types of outcome measures

In [ATBC 1994](#), three photographs of each eye were taken with a Canon fundus camera at 40 and 60 degree angles on Kodak Ektachrome 100 ASA slide film. These photographs were graded by one observer masked to the participant's treatment group. The following grades of maculopathy were used: 0 = none; I = dry maculopathy with hard drusen and/or pigmentary changes; II = soft macular drusen; III = disciform degeneration; IV = geographic atrophy.

In [PHS I](#) and [WHS](#), AMD was ascertained by self report: "Have you ever had macular degeneration diagnosed in your right or left eye?". If the participant answered yes to this question permission

was gained to contact their ophthalmologist or optometrist and further details were obtained from the medical records.

In [VECAT](#), photographs were taken with a Nidek 3-DX fundus camera on Kodachrome 64 ASA colour film. The photographs were graded at baseline independently by two trained graders. Early AMD (the primary outcome) was defined as soft drusen (distinct or indistinct) or pigmentary changes (hyperpigmentation or hypopigmentation) on photographic grading. On clinical grading this was large/soft drusen or non-geographical retinal pigment epithelium atrophy. [VECAT](#) used Bailey-Lovie visual acuity charts #4 and #5 (National Vision Research Institute, Australia).

### Excluded studies

See the '[Characteristics of excluded studies](#)' table for further information.

### Risk of bias in included studies

We considered all four trials to be at low risk of bias ([Figure 1](#); [Figure 2](#)). See 'Risk of bias' tables for each included study for details of the assessment.

**Figure 1. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.**




Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias): Visual acuity	Blinding of participants and personnel (performance bias): AMD	Blinding of outcome assessment (detection bias): Visual acuity	Blinding of outcome assessment (detection bias): AMD	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
ATBC	+	+		+		+	+	?
PHS I	+	+		+		+	+	+
VECAT	+	+	+	+	+	+	+	+
WHS	+	+	+	+	+	+	+	+

## Effects of interventions

See: [Summary of findings for the main comparison](#) Summary of findings: vitamin E; [Summary of findings 2](#) Summary of findings: beta-carotene

Overall 62,520 participants were included in the analyses of the four included trials. There were 863 cases of AMD in the antioxidant groups and 732 cases of AMD in the placebo groups ([Analysis 1.1](#)). The results of the four studies were reasonably consistent ( $I^2 = 16\%$ ). There was little evidence of any effect of antioxidant supplementation (RR 0.98, 95% CI 0.89 to 1.08).

Similarly with advanced AMD the trials were consistent ( $I^2 = 0\%$ ) and indicate little evidence of any effect of supplementation (RR 1.05, 95% CI 0.80 to 1.39) ([Analysis 1.2](#)). There were fewer advanced AMD events (110 cases in the antioxidant groups and 97 in the placebo groups).

Similar results were seen for analyses of alpha-tocopherol alone versus placebo ([Analysis 2.1](#); [Analysis 2.2](#)). A total of 40,887 people randomised in [ATBC](#), [VECAT](#) and [WHS](#) resulted in 447 cases of AMD in the alpha-tocopherol group and 458 in the placebo group ([Analysis 2.1](#)). The trial results were less consistent ( $I^2 = 53\%$ ). There was little evidence of any effect of supplementation with alpha-tocopherol on the incidence of AMD (RR 0.97, 95% CI 0.85 to 1.09). There were fewer cases of advanced AMD: 42 in the alpha-tocopherol groups and 31 in the placebo ([Analysis 2.2](#)). Again there was little evidence of any benefit from supplementation with a pooled RR in the direction of harm 1.34 (95% CI 0.84 to 2.14).

A total of 21,589 people were randomised into [ATBC](#) and [PHS](#)

[I](#) comparing beta-carotene with placebo ([Analysis 3.1](#); [Analysis 3.2](#)). There were 343 cases of AMD in the beta-carotene groups and 327 in the control groups ([Analysis 3.1](#)). The results of the trials were consistent ( $I^2 = 0\%$ ) and did not indicate any benefit of supplementation (RR 1.03, 95% CI 0.89 to 1.19). There were 65 cases of advanced AMD in the beta-carotene groups and 67 cases of advanced AMD in the control ([Analysis 3.2](#)). Again the results of the trials were consistent ( $I^2 = 0\%$ ) and indicated little effect of supplementation (RR 0.97, 95% CI 0.69 to 1.36).

## Adverse effects

None of the trials included in this review reported eye-related adverse effects. The main [ATBC](#) trial found an increased risk of lung cancer associated with beta-carotene supplementation ([ATBC 1994](#)), a finding that was repeated in the large [CARET](#) trial ([Omenn 1996](#)). Beta-carotene supplementation is contraindicated in people who smoke or have been exposed to asbestos. The [AREDS](#) study found an increased risk of hospitalisation for genitourinary conditions in men taking high-dose zinc supplementation ([Johnson 2007](#)) and increased yellowing of the skin ([AREDS 2001a](#)).

[Huang 2006](#) did not identify any consistent adverse effects of mineral and vitamin supplements but only included nine RCTs in their review. A subsequent Cochrane review including 78 trials with 296,707 participants concluded “*We found no evidence to support antioxidant supplements for primary or secondary prevention. Beta-carotene and vitamin E seem to increase mortality, and so may higher doses of vitamin A*” ([Bjelakovic 2012](#)).

## ADDITIONAL SUMMARY OF FINDINGS *[Explanation]*

Antioxidant supplement compared with placebo for prevention of AMD							
Patient or population: general population Settings: community Intervention: beta-carotene Comparison: placebo							
Outcomes	Illustrative comparative risks* (95% CI)			Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk		Corresponding risk				
	Placebo	Antioxidant supplementation					
Any AMD	180 per 1000	193 per 1000 (166 to 223)		RR 1.03 (0.89 to 1.19)	21,589 (3)	⊕⊕⊕⊕ high	
Advanced AMD	6 per 1000	6 per 1000 (4 to 8)		RR 0.97 (0.69 to 1.36)	21,589 (3)	⊕⊕⊕⊕ high	

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  
**AMD**: age-related macular degeneration; **CI**: confidence interval; **RR**: risk ratio

GRADE Working Group grades of evidence  
**High quality**: Further research is very unlikely to change our confidence in the estimate of effect.  
**Moderate quality**: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  
**Low quality**: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  
**Very low quality**: We are very uncertain about the estimate.

## DISCUSSION

### Summary of main results

This review provides evidence that people who take vitamin E or beta-carotene supplements do not reduce their risk of developing AMD ([Summary of findings for the main comparison](#); [Summary of findings 2](#)).

### Overall completeness and applicability of evidence

This review includes four large, high-quality studies which have randomised over 64,000 members of the population to antioxidant supplementation or placebo. Duration of supplementation has ranged from four to 12 years.

This review does not provide evidence as to the effects of other antioxidant vitamin and mineral supplements on the development of AMD, in particular it does not provide evidence as to the effects of commonly marketed vitamin combinations.

There are additional ongoing studies, including a further Physicians Health Study ([PHS II](#)). In the Women's Antioxidant Cardiovascular Study 8171 female health professionals who are at high risk for cardiovascular disease morbidity and mortality are being randomised using a 2 x 2 x 2 x 2 factorial design to vitamin C, vitamin E, folate, vitamin B6 and vitamin B12 supplementation ([WACS](#)).

Although generally regarded as safe, antioxidant supplements may have harmful effects. Beta-carotene increases the risk of lung cancer and overall there is some evidence of a small increased risk of mortality in people who take beta-carotene or vitamin E.

### Quality of the evidence

Overall the quality of the evidence was considered to be high ([Summary of findings for the main comparison](#); [Summary of findings 2](#)).

In [ATBC 1994](#) there was no association with the treatment group and development of early stages of the disease. If anything, there was a tendency for more cases to be present in the treatment rather than the placebo group. This was not statistically significant. One drawback of adding on a maculopathy study to a trial of primary prevention is that we have no information on maculopathy status before supplementation. Therefore we have to assume that (1) maculopathy was equally distributed across study groups at the start of the study and (2) most observed events occurred during the study period. It is likely that this is true for a reasonable proportion of the events as the maculopathy study began eight years after recruitment for the main trial and randomisation should have ensured equal distribution of maculopathy between the two groups.

Supplementation in this study began at age 50 to 69 and lasted five to eight years. Currently we do not know at what age antioxidant protection may be important. It may be that this was too late or too short a period of supplementation to show an effect. This study was conducted in Finnish male smokers and we have to be cautious in extrapolating the findings to other geographical areas, to people in other age groups, to women and to non-smokers. However, the incidence of AMD, particularly neovascular disease, is likely to be higher in smokers ([Klein 1993](#)) which means that they provide a good population to demonstrate any potential protective effects of antioxidant supplementation.

The results of [VECAT](#) similarly do not provide evidence of a benefit of supplementation in people with no or mild/borderline AMD, although again these studies have been underpowered to examine late-stage disease.

In the [PHS I](#) over 20,000 physicians received supplementation with beta-carotene over 12 years. There was little evidence of any benefit of beta-carotene supplementation. AMD was ascertained by medical record review and therefore may have been less accurate. However, there is no reason to suppose that the ascertainment will have been different in the treatment and control groups.

The Age-Related Eye Disease Study is not included in this review. However, there were 2180 people recruited with no or mild/borderline AMD ([AREDS 2001a](#)). The study reported no benefit of the study treatment for these people, however the number of events was small.

Although the number of people randomised in these studies is large there is still a degree of uncertainty in the pooled estimates. In the pooled analyses the risk ratios were largely around the null value or just above the null value.

### Agreements and disagreements with other studies or reviews

A recent systematic review of observational prospective studies also found little evidence of a protective effect of dietary antioxidants ([Chong 2007](#)). The only dietary antioxidant for which a reduction was seen was vitamin E, in contrast to the evidence from the trials included in this review. It is possible that natural vitamin E from dietary sources rather than artificial supplements has different effects, or alternatively high levels of dietary vitamin E might be a marker for other nutrients, for example, dietary fatty acids.

## AUTHORS' CONCLUSIONS

### Implications for practice

There is no evidence from randomised controlled trials that healthy people should take antioxidant vitamin and mineral supplements to prevent or delay the onset of AMD.

## Implications for research

There are a number of unanswered questions in the prevention of AMD. The hypothesis that antioxidant micronutrients may protect against the disease is a reasonable one. We do not know at what stage the protective effect may be important, nor the potential interactions with genetic effects and other risk factors for the disease such as smoking. The research to date shows that we cannot extrapolate to taking vitamin supplements without good evidence of their effectiveness and safety. Further trials are warranted to address this question and the results of ongoing trials are awaited. The small number of incident events in healthy people mean that trials need to be very large. Four large primary and secondary prevention trials in the field of cancer and cardiovascular disease have added on an examination of eye disease. This would seem to be a cost-effective way forward in research in this area.

## ACKNOWLEDGEMENTS

We are grateful to:

- the Systematic Review Training Unit at the Institute of Child Health, London for advice on the protocol for this review;
- all the trialists who responded to requests for information;
- peer reviewers Andrew Ness and Usha Chakravarthy for comments on an earlier version of this review.

We thank Katherine Henshaw who was an author on the original review. The Cochrane Eyes and Vision Group editorial team prepared and executed the electronic searches for this review. We are grateful to Anupa Shah and Iris Gordon for their assistance with the review process.

Richard Wormald (Co-ordinating Editor for CEVG) acknowledges financial support for his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.

## REFERENCES

### References to studies included in this review

#### ATBC *[published data only]*

- Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. *American Journal of Clinical Nutrition* 1995;**62**(6): 1427S–30S.
- Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. *Journal of the National Cancer Institute* 1996;**88**(21): 1560–70.
- Albanes D, Virtamo J, Rautalahti M, et al. Pilot study: The US-Finland lung cancer prevention trial. *Journal of Nutrition, Growth and Cancer* 1986;**3**(3):207–14.
- Albanes D, Virtamo J, Taylor PR, Rautalahti M, Pietinen P, Heinonen OP. Effects of supplemental beta-carotene, cigarette smoking, and alcohol consumption on serum carotenoids in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. *American Journal of Clinical Nutrition* 1997;**66**(2):366–72.
- Blumberg J, Block G. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study in Finland. *Nutrition Review* 1994;**52**(7):242–5.
- Buring JE, Hebert P, Hennekens CH. The alpha-tocopherol, beta-carotene lung cancer prevention trial of vitamin E and

- beta-carotene: the beginning of the answers. *Annals of Epidemiology* 1994;**4**(1):75.
- Glynn SA, Albanes D, Pietinen P, Brown CC, Rautalahti M, Tangrea JA, et al. Alcohol consumption and risk of colorectal cancer in a cohort of Finnish men. *Cancer Causes and Control* 1996;**7**(2):214–23.
- Hartman TJ, Albanes D, Pietinen P, Hartman AM, Rautalahti M, Tangrea JA, et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. *Cancer Epidemiology, Biomarkers and Prevention* 1998;**7**(4): 335–40.
- Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. *Journal of the National Cancer Institute* 1998;**90**:440–6.
- Laurila AL, Anttila T, Laara E, Bloigu A, Virtamo J, Albanes D, et al. Serological evidence of an association between *Chlamydia pneumoniae* infection and lung cancer. *International Journal of Cancer* 1997;**74**(1):31–4.
- Liede K, Hietanen J, Saxen L, Haukka J, Timonen T, Hayrinen Immonen R, et al. Long-term supplementation with alpha-tocopherol and beta-carotene and prevalence of oral mucosal lesions in smokers. *Oral Diseases* 1998;**4**(2): 78–83.
- Liede KE, Alfthan G, Hietanen JH, Haukka JK, Saxen LM, Heinonen OP. Beta-carotene concentration in buccal mucosal cells with and without dysplastic oral leukoplakia

- after long-term beta-carotene supplementation in male smokers. *European Journal of Clinical Nutrition* 1998;**52**: 872–6.
- Liede KE, Haukka JK, Saxen LM, Heinonen OP. Increased tendency towards gingival bleeding caused by joint effect of alpha-tocopherol supplementation and acetylsalicylic acid. *Annals of Medicine* 1998;**30**(6):542–6.
- Pietinen P, Rimm EB, Korhonen P, Hartman AM, Willett WC, Albanes D, et al. Intake of dietary fiber and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. *Circulation* 1996;**94**(11):2720–7.
- Rapola JM, Virtamo J, Haukka JK, Heinonen OP, Albanes D, Taylor PR, et al. Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial. *JAMA* 1996;**275**(9):693–8.
- Rapola JM, Virtamo J, Ripatti S, Haukka JK, Huttunen JK, Albanes D, et al. Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris. *Heart* 1998;**79**(5):454–8.
- Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. *Lancet* 1997;**349**(9067):1715–20.
- Teikari JM, Laatikainen L, Rapola JM, Virtamo J, Haukka J, Liesto K, et al. Retinal vascular changes following supplementation with alpha-tocopherol or beta-carotene. *Acta Ophthalmologica Scandinavica* 1998;**76**(1):68–73.
- \* Teikari JM, Laatikainen L, Virtamo J, Haukka J, Rautalahti M, Liesto K, et al. Six-year supplementation with alpha-tocopherol and beta-carotene and age-related maculopathy. *Acta Ophthalmologica Scandinavica* 1998;**76**(2):224–9.
- Teikari JM, Rautalahti M, Haukka J, Jarvinen P, Hartman AM, Virtamo J, et al. Incidence of cataract operations in Finnish male smokers unaffected by alpha tocopherol or beta carotene supplements. *Journal of Epidemiology and Community Health* 1998;**52**(7):468–72.
- Teikari JM, Virtamo J, Rautalahti M, Palmgren J, Liesto K, Heinonen OP. Long-term supplementation with alpha-tocopherol and beta-carotene and age-related cataract. *Acta Ophthalmologica Scandinavica* 1997;**75**(6):634–40.
- The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. *Annals of Epidemiology* 1994;**4**(1):1–10.
- The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *New England Journal of Medicine* 1994;**330**(15): 1029–35.
- Tornwall M, Virtamo J, Haukka JK, Aro A, Albanes D, Edwards BK, et al. Effect of alpha-tocopherol (vitamin E) and beta-carotene supplementation on the incidence of intermittent claudication in male smokers. *Arteriosclerosis, Thrombosis and Vascular Biology* 1997;**17**(12):3475–80.
- Varis K, Taylor PR, Sipponen P, Samloff IM, Heinonen OP, Albanes D, et al. Gastric cancer and premalignant lesions in atrophic gastritis: a controlled trial on the effect of supplementation with alpha-tocopherol and beta-carotene. The Helsinki Gastritis Study Group. *Scandinavian Journal of Gastroenterology* 1998;**33**(3):294–300.
- Virtamo J, Rapola JM, Ripatti S, Heinonen OP, Taylor PR, Albanes D, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. *Archives of Internal Medicine* 1998;**158**(6):668–75.

#### PHS I {published data only}

- Belanger C, Buring JE, Cook N, Eberlein K, Goldhaber SZ, Gordon D, et al. Final report on the aspirin component of the ongoing physicians' health study. *New England Journal of Medicine* 1989;**321**(3):129–35.
- Berger K, Kase CS, Buring JE. Interobserver agreement in the classification of stroke in the physicians' health study. *Stroke* 1996;**27**(2):238–42.
- Buring JE, Hebert P, Romero J, Kittross A, Cook N, Manson J, et al. Migraine and subsequent risk of stroke in the Physicians' Health Study. *Archives of Neurology* 1995;**52**(2):129–34.
- Buring JE, Hennekens CH. Cost and efficiency in clinical trials: The U.S. physicians' health study. *Statistics in Medicine* 1990;**9**(1-2):29–33.
- Cairns J, Cohen L, Colton T, DeMets DL, Deykin D, Friedman L, et al. Issues in the early termination of the aspirin component of the Physicians' Health Study. *Annals of Epidemiology* 1991;**1**(5):395–405.
- Camargo CA Jr, Stampfer MJ, Glynn RJ, Gaziano JM, Manson JE, Goldhaber SZ, et al. Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians. *Circulation* 1997;**95**(3):577–80.
- Christen WG, Ajani UA, Glynn RJ, Manson JE, Schaumberg DA, Chew EC, et al. Prospective cohort study of antioxidant vitamin supplement use and the risk of age-related maculopathy. *American Journal of Epidemiology* 1999;**149**(5):476–84.
- Christen WG, Glynn RJ, Manson JE, Agani UA, Buring JE. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. *JAMA* 1996;**276**(14): 1147–51.
- Christen WG, Manson JE, Glynn RJ, Ajani UA, Schaumberg DA, Sperduto RD, et al. Low-dose aspirin and risk of cataract and subtypes in a randomized trial of U.S. physicians. *Ophthalmic Epidemiology* 1998;**5**(3):133–42.
- \* Christen WG, Manson JE, Glynn RJ, Gaziano JM, Chew EY, Buring JE, et al. Beta carotene supplementation and age-related maculopathy in a randomized trial of US physicians. *Archives of Ophthalmology* 2007;**125**(3):333–9.
- Christen WG, Manson JE, Seddon JM, Glynn RJ, Buring JE, Rosner B, et al. A prospective study of cigarette smoking and risk of cataract in men. *JAMA* 1992;**268**(8):989–93.
- Fotouhi N, Meydani M, Santos MS, Meydani SN,



- Hennekens CH, Gaziano JM. Carotenoid and tocopherol concentrations in plasma, peripheral blood mononuclear cells, and red blood cells after long-term beta-carotene supplementation in men. *American Journal of Clinical Nutrition* 1996;**63**(4):553–8.
- Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. *Journal of the National Cancer Institute* 1993;**85**(15):1220–4.
- Glynn RJ, Christen WG, Manson JE, Bernheimer J, Hennekens CH. Body mass index. An independent predictor of cataract. *Archives of Ophthalmology* 1995;**113**(9):1131–7.
- Guallar E, Hennekens CH, Sacks FM, Willett WC, Stampfer MJ. A prospective study of plasma fish oil levels and incidence of myocardial infarction in U.S. male physicians. *Journal of the American College of Cardiology* 1995;**25**(2):387–94.
- Hebert PR, Rich Edwards JW, Manson JE, Ridker PM, Cook NR, O'Connor GT, et al. Height and incidence of cardiovascular disease in male physicians. *Circulation* 1993;**88**(4 (Pt 1)):1437–43.
- Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *New England Journal of Medicine* 1996;**334**(18):1145–9.
- Hennekens CH, Eberlein K. A randomized trial of aspirin and beta-carotene among U.S. physicians. *Preventive Medicine* 1985;**14**(2):165–8.
- Lang JM, Buring JE, Rosner B, Cook N, Hennekens CH. Estimating the effect of the run-in on the power of the Physicians' Health Study. *Statistics in Medicine* 1991;**10**(10):1585–93.
- Lee IM, Hennekens CH, Berger K, Buring JE, Manson JE. Exercise and risk of stroke in male physicians. *Stroke* 1999;**30**(1):1–6.
- Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. *Cancer Research* 1997;**57**(6):1098–102.
- Manson JE, Buring JE, Satterfield S, Hennekens CH. Baseline characteristics of participants in the Physicians' Health Study: a randomized trial of aspirin and beta-carotene in U.S. physicians. *American Journal of Preventive Medicine* 1991;**7**(3):150–4.
- Manson JE, Christen WG, Seddon JM, Glynn RJ, Hennekens CH. A prospective study of alcohol consumption and risk of cataract. *American Journal of Preventive Medicine* 1994;**10**(3):156–61.
- Morris MC, Manson JE, Rosner B, Buring JE, Willett WC, Hennekens CH. Fish consumption and cardiovascular disease in the physicians' health study: a prospective study. *American Journal of Epidemiology* 1995;**142**(2):166–75.
- O'Donnell CJ, Ridker PM, Glynn RJ, Berger K, Ajani U, Manson JE, et al. Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. *Circulation* 1997;**95**(5):1132–7.
- Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. *Circulation* 1998;**97**(5):425–8.
- Ridker PM, Hennekens CH, Roitman Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. *Lancet* 1998;**351**(9004):88–92.
- Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. *Annals of Internal Medicine* 1991;**114**(10):835–9.
- Robbins AS, Manson JE, Lee IM, Satterfield S, Hennekens CH. Cigarette smoking and stroke in a cohort of U.S. male physicians. *Annals of Internal Medicine* 1994;**120**(6):458–62.
- Salvini S, Stampfer MJ, Barbieri RL, Hennekens CH. Effects of age, smoking and vitamins on plasma DHEAS levels: a cross-sectional study in men. *Journal of Clinical Endocrinology and Metabolism* 1992;**74**(1):139–43.
- Santos MS, Gaziano JM, Leka LS, Beharka AA, Hennekens CH, Meydani SN. Beta-carotene-induced enhancement of natural killer cell activity in elderly men: an investigation of the role of cytokines. *American Journal of Clinical Nutrition* 1998;**68**(1):164–70.
- Santos MS, Leka LS, Ribaya Mercado JD, Russell RM, Meydani M, Hennekens CH, et al. Short- and long-term beta-carotene supplementation do not influence T cell-mediated immunity in healthy elderly persons. *American Journal of Clinical Nutrition* 1997;**66**(5):917–24.
- Santos MS, Meydani SN, Leka L, Wu D, Fotouhi N, Meydani M, et al. Natural killer cell activity in elderly men is enhanced by beta-carotene supplementation. *American Journal of Clinical Nutrition* 1996;**64**:772–7.
- Satterfield S, Greco PJ, Goldhaber SZ, Stampfer MJ, Swartz SL, Stein EA, et al. Biochemical markers of compliance in the Physicians' Health Study. *American Journal of Preventive Medicine* 1990;**6**(5):290–4.
- Schaumburg DA, Hennekens CH. Effect of 12 years of beta-carotene supplementation on malignant non-melanoma skin cancer: results from the Physicians' Health Study. *American Journal of Epidemiology* 1996;**143**:S9.
- Seddon JM, Christen WG, Manson JE, LaMotte FS, Glynn RJ, Buring JE, et al. The use of vitamin supplements and the risk of cataract among US male physicians. *American Journal of Public Health* 1994;**84**(5):788–92.
- Stampfer MJ, Buring JE, Willett W, Rosner B, Eberlein K, Hennekens CH. The 2 x 2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians. *Statistics in Medicine* 1985;**4**(2):111–6.
- Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. *Stroke* 1994;**25**(10):1132–7.

1924–30.

Zee RY, Ridker PM, Stampfer MJ, Hennekens CH, Lindpaintner K. Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke. *Circulation* 1999;**99**(3):340–3.

#### **VECAT {unpublished data only}**

Garrett SKM, McNeil JJ, Silagy C, Sinclair M, Thomas AP, Robman LD, et al. Methodology of the VECAT study: vitamin E intervention in cataract and age-related maculopathy. *Ophthalmic Epidemiology* 1999;**6**:195–208. Robman LD, Tikellis G, Garrett SKM, Harper CA, McNeil JJ, Taylor HR, et al. Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. *Australian and New Zealand Journal of Ophthalmology* 1999;**27**:410–6.

\* Taylor H, Tikellis G, Robman L, McCarty C, McNeil J. Vitamin E supplementation and macular degeneration: randomised controlled trial. *BMJ* 2002;**325**:325–11. Taylor HR, Tikellis G, Robman LD, McCarty CA, McNeil. Vitamin E supplementation and age-related maculopathy (abstract). *Investigative Ophthalmology and Visual Science* 2001;**42**:S311.

#### **WHS {published data only}**

Buring JE, Hennekens CH. Randomized trials of primary prevention of cardiovascular disease in women. An investigator's view. *Annals of Epidemiology* 1994;**4**(2): 111–4.

Christen WG, Glynn RJ, Chew EY, Buring JE. Vitamin E and age-related macular degeneration in a randomized trial of women. *Ophthalmology* 2010;**117**(6):1163–8.

### **References to studies excluded from this review**

#### **ADSC {published data only}**

Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. *New England Journal of Medicine* 1997;**336**(17):1216–22.

#### **Andrews 1969 {published data only}**

Andrews J, Letcher M, Brook M. Vitamin C supplementation in the elderly: a 17-month trial in an old persons' home. *British Medical Journal* 1969;**2**(5654): 416–8.

#### **AREDS {published data only}**

\* Age Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Archives of Ophthalmology* 2001;**119**(10):1417–36.

#### **Benner 1994 {published data only}**

Benner SE, Lippman SM, Hong WK. Retinoid chemoprevention of second primary tumors. *Seminars in Hematology* 1994;**31**(4 Suppl 5):26–30.

#### **Benton 1995 {published data only}**

\* Benton D, Fordy J, Haller J. The impact of long-term vitamin supplementation on cognitive functioning. *Psychopharmacology* 1995;**117**(3):298–305.

#### **Blok 1997 {published data only}**

Blok WL, Deslypere JP, Demacker PN, van der Ven Jongekrijg J, Hectors MP, van der Meer JW, et al. Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. *European Journal of Clinical Investigation* 1997;**27**(12):1003–8.

#### **Bogden 1990 {published data only}**

Bogden JD, Oleske JM, Lavenhar MA, Munves EM, Kemp FW, Bruening KS, et al. Effects of one year of supplementation with zinc and other micronutrients on cellular immunity in the elderly. *Journal of the American College of Nutrition* 1990;**9**(3):214–25.

#### **Bone 2010 {published data only}**

Bone RA, Landrum JT. Dose-dependent response of serum lutein and macular pigment optical density to supplementation with lutein esters. *Archives of Biochemistry and Biophysics* 2010;**504**(1):50–5.

#### **Brewer 1997 {published data only}**

Brewer GJ, Johnson V, Kaplan J. Treatment of Wilson's disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function. *Journal of Laboratory and Clinical Medicine* 1997;**129**(6):649–52.

#### **Brown 1998 {published data only}**

Brown BG, Zhao XQ, Chait A, Frohlich J, Cheung M, Heise N, et al. Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design. *Canadian Journal of Cardiology* 1998;**14 Suppl A**: 6A–13A.

#### **Bussey 1982 {published data only}**

Bussey HJ, DeCosse JJ, Deschner EE, Evers AA, Lesser ML, Morson BC, et al. A randomized trial of ascorbic acid in polyposis coli. *Cancer* 1982;**50**(7):1434–9.

#### **Caligiuri 1997 {published data only}**

Caligiuri MP, Lohr JB, Rotrosen J, Adler L, Lavori P, Edson R, et al. Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study 394. *Psychopharmacology* 1997;**132**(1):61–6.

#### **CARET {published data only}**

\* Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *New England Journal of Medicine* 1996;**334**(18): 1150–5.

#### **CARMIS {published data only}**

Piermarocchi S, Saviano S, Parisi V, Tedeschi M, Panozzo G, Scarpa G, et al. Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year results of a randomized study. *European Journal of Ophthalmology* 2011;**22**(2): 216–25.

- CCSG {published data only}**  
Roncucci L, Di Donato P, Carati L, Ferrari A, Perini M, Bertoni G, et al. Antioxidant vitamins or lactulose for the prevention of the recurrence of colorectal adenomas. Colorectal Cancer Study Group of the University of Modena and the Health Care District 16. *Diseases of the Colon and Rectum* 1993;**36**(3):227–34.
- Chandra 1992 {published data only}**  
\* Chandra RK. Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects. *Lancet* 1992;**340**(8828):1124–7.
- CHAOS {published data only}**  
\* Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). *Lancet* 1996;**347**(9004):781–6.
- Clausen 1989 {published data only}**  
Clausen J, Nielsen SA, Kristensen M. Biochemical and clinical effects of an antioxidative supplementation of geriatric patients. A double blind study. *Biological Trace Element Research* 1989;**20**(1–2):135–51.
- Constans 1996 {published data only}**  
Constans J, Delmas Beauvieux MC, Sergeant C, Peuchant E, Pellegrin JL, Pellegrin I, et al. One-year antioxidant supplementation with beta-carotene or selenium for patients infected with human immunodeficiency virus: a pilot study. *Clinical Infectious Diseases* 1996;**23**(3):654–6.
- Constantino 1988 {published data only}**  
Costantino JP, Kuller LH, Begg L, Redmond CK, Bates MW. Serum level changes after administration of a pharmacologic dose of beta-carotene. *American Journal of Clinical Nutrition* 1988;**48**(5):1277–83.
- Cucinotta 1994 {published data only}**  
Cucinotta D, Senin U, Girardello R, Crepaldi G. Positively effect on patients with senile dementia of alzheimer type (SDAT): a double blind multicentre trial versus ascorbic acid and citicoline. *Journal of Neurology* 1994;**241**:S129.
- DATATOP {published data only}**  
Shoulson I, Fahn S, Oakes D, Lang A, Langston JW, LeWitt P, et al. DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. *Archives of Neurology* 1989;**46**(10):1052–60.
- DeCosse 1989 {published data only}**  
DeCosse JJ, Miller HH, Lesser ML. Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. *Journal of the National Cancer Institute* 1989;**81**(17):1290–7.
- de Klerk 1998 {published data only}**  
de Klerk NH, Musk AW, Ambrosini GL, Eccles JL, Hansen J, Olsen N, et al. Vitamin A and cancer prevention II: comparison of the effects of retinol and beta-carotene. *International Journal of Cancer* 1998;**75**:362–7.
- Dobson 1984 {published data only}**  
Dobson HM, Muir MM, Hume R. The effect of ascorbic acid on the seasonal variations in serum cholesterol levels. *Scottish Medical Journal* 1984;**29**(3):176–82.
- ECP-IM {published data only}**  
Reed PI, Johnston BJ. Primary prevention of gastric cancer - The ECP-IM intervention study. *Acta Endoscopica* 1995;**25**:45–54.
- EUROSCAN {published data only}**  
Cianfriglia F, Iofrida RV, Calpicchio A, Manieri A. The chemoprevention of oral carcinoma with vitamin A and/or N-acetylcysteine. *Minerva Stomatologica* 1994;**43**(6):255–61.
- Fairley 1996 {published data only}**  
Fairley CK, Tabrizi SN, Chen S, Baghurst P, Young H, Quinn M, et al. A randomized clinical trial of beta carotene vs placebo for the treatment of cervical HPV infection. *International Journal of Gynecological Cancer* 1996;**6**(3):225–30.
- Falsani 2010 {published data only}**  
Falsani B, Piccardi M, Minnella A, Savastano C, Capoluongo E, Fadda A, et al. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. *Investigative Ophthalmology and Visual Science* 2010;**51**(12):6118–24.
- Fontham 1995 {published data only}**  
Fontham ET, Malcom GT, Singh VN, Ruiz B, Schmidt B, Correa P. Effect of beta-carotene supplementation on serum alpha-tocopherol concentration. *Cancer Epidemiology, Biomarkers and Prevention* 1995;**4**(7):801–3.
- Galan 1997 {published data only}**  
Galan P, Preziosi P, Monget AL, Richard MJ, Arnaud J, Lesourd B, et al. Effects of trace element and/or vitamin supplementation on vitamin and mineral status, free radical metabolism and immunological markers in elderly long term-hospitalized subjects. Geriatric Network MIN. VIT. AOX. *International Journal for Vitamin and Nutrition Research* 1997;**67**(6):450–60.
- Garawal 1995 {published data only}**  
Garewal H, Meyskens F, Katz RV, Friedman S, Morse DE, Alberts D, et al. Beta-carotene produces sustained remissions in oral leukoplakia: results of a 1 year randomized, controlled trial. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1995; Vol. 14:ABS. A1623.
- GISSI {published data only}**  
Marchioli R, Di Pasquale A. The biochemical, pharmacological and epidemiological reference picture of the GISSI-Prevention. The Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico [Il quadro di riferimento biochimico, farmacologico, epidemiologico del GISSI-Prevenzione]. *Giornale Italiano di Cardiologia* 1993;**23**(9):933–64.
- HOPE {published data only}**  
Gerstein HC, Bosch J, Pogue J, Taylor DW, Zinman B, Yusuf S. Rationale and design of a large study to evaluate

- the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. *Diabetes Care* 1996;**19**(11):1225–8.
- Johnson 1997** *{published data only}*  
Johnson MA, Porter KH. Micronutrient supplementation and infection in institutionalized elders. *Nutrition Review* 1997;**55**(11):400–4.
- Jyothirmayi 1996** *{published data only}*  
Jyothirmayi R, Ramadas K, Varghese C, Jacob R, Nair MK, Sankaranarayanan R. Efficacy of vitamin A in the prevention of loco-regional recurrence and second primaries in head and neck cancer. *European Journal of Cancer Part B Oral Oncology* 1996;**32B**(6):373–6.
- Kuklinski 1994** *{published data only}*  
Kuklinski B, Weissenbacher E, Fahrlich A. Coenzyme Q10 and antioxidants in acute myocardial infarction. *Molecular Aspects of Medicine* 1994;**Supplement**:S143–7.
- Kvansakul 2006** *{published data only}*  
Kvansakul J, Rodriguez-Carmona M, Edgar DF, Barker FM, Kopcke W, Schalch W, et al. Supplementation with the carotenoids lutein or zeaxanthin improves human visual performance. *Ophthalmic and Physiological Optics* 2006;**26**(4):362–71.
- Leng 1997** *{published data only}*  
Leng GC, Lee AJ, Fowkes FG, Horrobin D, Jepson RG, Lowe GD, et al. Randomized controlled trial of antioxidants in intermittent claudication. *Vascular Medicine* 1997;**2**(4):279–85.
- Li 1992** *{published data only}*  
Li WG. Preliminary observations on effect of selenium yeast on high risk populations with primary liver cancer. *Chung Hua Yu Fang I Hsueh Tsa Chih - Chinese Journal of Preventive Medicine* 1992;**26**(5):268–71.
- LINXIAN** *{published data only}*  
Li JY, Li B, Blot WJ, Taylor PR. Preliminary report on the results of nutrition prevention trials of cancer and other common diseases among residents in Linxian, China. *Chung Hua Chung Liu Tsa Chih - Chinese Journal of Oncology* 1993;**15**(3):165–81.  
Sperduto RD, Hu TS, Milton RC, Zhao JL, Everett DF, Cheng QF, et al. The Linxian cataract studies. Two nutrition intervention trials. *Archives of Ophthalmology* 1993;**111**(9):1246–53.
- Mayne 1998** *{published data only}*  
Mayne ST, Cartmel B, Silva F, Kim CS, Fallon BG, Briskin K, et al. Effect of supplemental beta-carotene on plasma concentrations of carotenoids, retinol, and alpha-tocopherol in humans. *American Journal of Clinical Nutrition* 1998;**68**(3):642–7.
- McKeown 1988** *{published data only}*  
McKeown Eyssen G, Holloway C, Jazmaji V, Bright See E, Dion P, Bruce WR. A randomized trial of vitamins C and E in the prevention of recurrence of colorectal polyps. *Cancer Research* 1988;**48**(16):4701–5.
- Meyskens 1994** *{published data only}*  
Meyskens Jr FL, Liu PY, Tuthill RJ, Sondak VK, Fletcher WS, Jewell WR, et al. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. *Journal of Clinical Oncology* 1994;**12**(10):2060–5.
- Munoz 1987** *{published data only}*  
Munoz N, Wahrendorf J, Bang LJ, Crespi M, Thurnham DI, Day NE, et al. No effect of riboflavin, retinol, and zinc on prevalence of precancerous lesions of oesophagus. Randomised double-blind intervention study in high-risk population of China. *Lancet* 1985;**2**(8447):111–4.
- Munoz 1996** *{published data only}*  
Munoz N, Vivas J, Buiatti E, Kato I, Oliver W. Chemoprevention trial on precancerous lesions of the stomach in Venezuela: summary of study design and baseline data. *IARC Scientific Publications* 1996;**139**:125–33.
- Nambour 1995** *{published data only}*  
Ambler JS, Hirst LW, Clarke CV, Green AC. The Nambour study of ocular disease. I. Design, study population and methodology. *Ophthalmic Epidemiology* 1995;**2**(3):137–44.
- NCT00718653** *{published data only}*  
NCT00718653. Effects of antioxidants on human macular pigments. <http://www.clinicaltrials.gov/ct2/show/NCT00718653> (accessed 21 September 2010).
- NCT01208948** *{published data only}*  
NCT01208948. Clinical trial on alpha lipoic acid in diabetic macular edema (RETIPON). <http://www.clinicaltrials.gov/ct2/show/NCT01208948> (accessed 17 January 2012).
- Newsome, 2008** *{published data only}*  
Newsome DA. A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. *Current Eye Research* 2008;**33**(7):591–8.
- NPCSG** *{published data only}*  
Clark LC, Combs Jr GF, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. *JAMA* 1996;**276**(24):1957–63.
- Pastorino 1991** *{published data only}*  
Pastorino U, Soresi E, Clerici M, Chiesa G, Belloni PA, Ongari M, et al. Lung cancer chemoprevention with retinol palmitate. Preliminary data from a randomized trial on stage Ia non small-cell lung cancer. *Acta Oncologica* 1988;**27**(6b):773–82.
- Pemp 2010** *{published data only}*  
Pemp B, Polska E, Karl K, Lasta M, Minichmayr A, Garhofer G, et al. Effects of antioxidants (AREDS medication) on ocular blood flow and endothelial function in an endotoxin-induced model of oxidative stress in humans. *Investigative Ophthalmology and Visual Science* 2010;**51**(1):2–6.

- Peng 1993** *{published data only}*  
 Peng YM, Peng YS, Lin Y, Moon T, Baier M. Micronutrient concentrations in paired skin and plasma of patients with actinic keratoses: effect of prolonged retinol supplementation. *Cancer Epidemiology, Biomarkers and Prevention* 1993;**2**(2):145–50.
- PPP** *{published data only}*  
 Primary prevention project (PPP) in the Mario Negri Institute in Milan. *Ricerca E Pratica* 1996;**12**:175–218.
- PPSG** *{published data only}*  
 Greenberg ER, Baron JA, Tosteson TD, Freeman DH Jr, Beck GJ, Bond JH, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. *New England Journal of Medicine* 1994;**331**(3):141–7.
- Prasad 1995** *{published data only}*  
 Prasad MP, Mukundan MA, Krishnaswamy K. Micronuclei and carcinogen DNA adducts as intermediate end points in nutrient intervention trial of precancerous lesions in the oral cavity. *European Journal of Cancer Part B Oral Oncology* 1995;**31B**(3):155–9.
- REACT** *{published data only}*  
 Chylack Jr LT, Wolfe JK, Friend J, Tung W, Singer DM, Brown NP, et al. Validation of methods for the assessment of cataract progression in the Roche European-American Anticataract Trial (REACT). *Ophthalmic Epidemiology* 1995;**2**(2):59–75.
- Recchia 1995** *{published data only}*  
 Recchia F, Sica G, de Filippis S, Discepoli S, Rea S, Torchio P, et al. Interferon-beta, retinoids, and tamoxifen in the treatment of metastatic breast cancer: a phase II study. *Journal of Interferon and Cytokine Research* 1995;**15**(7):605–10.
- Rein 2007** *{published data only}*  
 Rein DB, Saaddine JB, Wittenborn JS, Wirth KE, Hoerger TJ, Narayan KM, et al. Cost-effectiveness of vitamin therapy for age-related macular degeneration. *Ophthalmology* 2007;**114**(7):1319–26.
- Ret Pig 1993** *{published data only}*  
 Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel DiFranco C, et al. Randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. *Archives of Ophthalmology* 1993;**111**(6):761–72.  
 Norton EWD, Marmor MF, Clowes DD, Gamel JW, Barr CC, Fielder AR, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa (2). *Archives of Ophthalmology* 1993;**111**(11):1460–6.
- Rodriguez-Carmona 2006** *{published data only}*  
 Rodriguez-Carmona M, Kvensakul J, Harlow JA, Köpcke W, Schalch W, Barbur JL. The effects of supplementation with lutein and/or zeaxanthin on human macular pigment density and colour vision. *Ophthalmic and Physiological Optics* 2006;**26**(2):137–47.
- SAINTS** *{published data only}*  
 NCT00893724. Supplemental adjuvants for intracellular nutrition and treatment (SAINTS). <http://www.clinicaltrials.gov/ct2/show/NCT00893724> (accessed 20 March 2012).
- SCPS 1989** *{published data only}*  
 Greenberg ER, Baron JA, Stevens MM, Stukel TA, Mandel JS, Spencer SK, et al. The Skin Cancer Prevention Study: design of a clinical trial of beta-carotene among persons at high risk for nonmelanoma skin cancer. *Controlled Clinical Trials* 1989;**10**(2):153–66.  
 Greenberg ER, Baron JA, Stukel TA, Stevens MM, Mandel JS, Spencer SK, et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. *New England Journal of Medicine* 1990;**323**(12):789–95.
- SECURE** *{published data only}*  
 Lonn EM, Yusuf S, Doris CI, Sabine MJ, Dzavik V, Hutchison K, et al. Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE. *American Journal of Cardiology* 1996;**78**(8):914–9.
- Shandong 1998** *{published data only}*  
 Gail MH, You WC, Chang YS, Zhang L, Blot WJ, Brown LM, et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. *Controlled Clinical Trials* 1998;**19**(4):352–69.
- Sharma 1989** *{published data only}*  
 Sharma YR, Vajpayee RB, Bhatnagar R, Mohan M, Azad RV, Kumar M, et al. Systemic aspirin and systemic vitamin E in senile cataracts: cataract V. *Indian Journal of Ophthalmology* 1989;**37**(3):134–41.
- Steiner 1995** *{published data only}*  
 Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. *American Journal of Clinical Nutrition* 1995;**62**(6 Suppl):1381S–4S.
- SUVIMAX** *{published data only}*  
 Girodon F, Blache D, Monget AL, Lombart M, Brunet Lecompte P, Arnaud J, et al. Effect of a two-year supplementation with low doses of antioxidant vitamins and/or minerals in elderly subjects on levels of nutrients and antioxidant defense parameters. *Journal of the American College of Nutrition* 1997;**16**(4):357–65.  
 Hercberg S, Galan P, Preziosi P, Rousset AM, Arnaud J, Richard MJ, et al. Background and rationale behind the SU.VI.MAX Study, a prevention trial using nutritional doses of a combination of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. SUpplementation en Vitamines et Mineraux AntioXydants Study. *International Journal for Vitamin and Nutrition Research* 1998;**68**(1):3–20.
- SWSCPSG** *{published data only}*  
 Levine N, Moon TE, Cartmel B, Bangert JL, Rodney S, Dong Q, et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. *Cancer Epidemiology, Biomarkers and Prevention* 1997;**6**(11):957–61.

**Takamatsu 1995** {published data only}

Takamatsu S, Takamatsu M, Satoh K, Imaizumi T, Yoshida H, Hiramoto M, et al. Effects on health of dietary supplementation with 100 mg d-alpha-tocopheryl acetate, daily for 6 years. *Journal of International Medical Research* 1995;**23**(5):342–57.

**Tomeo 1995** {published data only}

Tomeo AC, Geller M, Watkins TR, Gapor A, Bierenbaum ML. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. *Lipids* 1995;**30**(12):1179–83.

**Tsubono 1997** {published data only}

Tsubono Y, Okubo S, Hayashi M, Kakizoe T, Tsugane S. A randomized controlled trial for chemoprevention of gastric cancer in high-risk Japanese population; study design, feasibility and protocol modification. *Japanese Journal of Cancer Research* 1997;**88**(4):344–9.

**WAFACS** {published data only}

NCT00000161. Randomized trials of vitamin supplements and eye disease. <http://clinicaltrials.gov/ct2/show/NCT00000161> (accessed 7 February 2008).

**Wahlqvist 1994** {published data only}

Wahlqvist ML, Wattanapenpaiboon N, Macrae FA, Lambert JR, MacLennan R, Hsu Hage BH. Changes in serum carotenoids in subjects with colorectal adenomas after 24 mo of beta-carotene supplementation. Australian Polyp Prevention Project Investigators. *American Journal of Clinical Nutrition* 1994;**60**(6):936–43.

**Wong 2010** {published data only}

Wong WT, Kam W, Cunningham D, Harrington M, Hammel K, Meyerle CB, et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. *Investigative Ophthalmology and Visual Science* 2010;**51**(12):6131–9.

**Wright 1985** {published data only}

Wright JP, Mee AS, Parfitt A, Marks IN, Burns DG, Sherman M, et al. Vitamin A therapy in patients with Crohn's disease. *Gastroenterology* 1985;**88**(2):512–4.

**Yu 1991** {published data only}

Yu SY, Zhu YJ, Li WG, Huang QS, Huang CZ, Zhang QN, et al. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. *Biological Trace Element Research* 1991;**29**(3):289–94.

**YUNNAN** {published data only}

Yu SY, Mao BL, Xiao P, Yu WP, Wang YL, Huang CZ, et al. Intervention trial with selenium for the prevention of lung cancer among tin miners in Yunnan, China. A pilot study. *Biological Trace Element Research* 1990;**24**(2):105–8.

**Zaridze 1993** {published data only}

Zaridze D, Evstifeeva T, Boyle P. Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer. *Annals of Epidemiology* 1993;**3**(3):225–34.

**References to ongoing studies****AREDS2** {published data only}

Hubbard LD, Danis RP, Neider MW, Thayer DW, Wabers HD, White JK, et al. Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. *Investigative Ophthalmology and Visual Science* 2008;**49**(8):3269–82.

**LIMPIA** {published data only}

NCT01269697. Lutein influence on macula of persons issued from AMD parents (LIMPIA). <http://clinicaltrials.gov/ct2/show/NCT01269697> (accessed 6 April 2012).

**PHS II** {published data only}

Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II - a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease and review of results of completed trials. *Annals of Epidemiology* 2000;**10**(2):125–34.

**SELECT** {published data only}

Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA* 2009;**301**(1):39–51.

**WACS** {unpublished data only}

Manson JE, Gaziano JM, Spelsberg A, Ridker PM, Cook NR, Buring JE, et al. A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group. *Annals of Epidemiology* 1995;**5**(4):261–9.

**Additional references****AREDS 2001a**

Age Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Archives of Ophthalmology* 2001;**119**(10):1417–36.

**AREDS 2001b**

The Age-Related Eye Disease Research Study Group. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. *American Journal of Ophthalmology* 2001;**132**(5):668–81.

**ATBC 1994**

The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *New England Journal of Medicine* 1994;**330**(15):1029–35.

**Bjelakovic 2012**

Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane Database of Systematic Reviews* 2012, Issue 3. [DOI: 10.1002/14651858.CD007176.pub2]

**Bunce 2006**

Bunce Catey, Wormald Richard. Leading causes of certification for blindness and partial sight in England & Wales. *BMC Public Health* 2006;**6**(1):58.

**Chong 2007**

Chong EW-T, Wong TY, Kreis AJ, Simpson JA, Guymer RH. Dietary antioxidants and primary prevention of age-related macular degeneration: a systematic review and meta-analysis. *BMJ* 2007;**335**(7623):755.

**Christen 1996**

Christen WG, Glynn RJ, Hennekens CH. Antioxidants and age-related eye disease. Current and future perspectives. *Annals of Epidemiology* 1996;**6**(1):60–6.

**Evans 2001**

Evans JR. Risk factors for age-related macular degeneration. *Progress in Retinal Eye Research* 2001;**20**:227–53.

**Evans 2006**

Evans J. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. *Cochrane Database of Systematic Reviews* 2006, Issue 2. [DOI: 10.1002/14651858.CD000254.pub2]

**Glanville 2006**

Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. *Journal of the Medical Library Association* 2006;**94**(2):130–6.

**Higgins 2011**

Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

**Huang 2006**

Huang H-Y, Caballero B, Chang S, Alberg AJ, Semba RD, Schneyer CR, et al. The efficacy and safety of multivitamin

and mineral supplement use to prevent cancer and chronic disease in adults: a systematic review for a National Institutes of Health State-of-the-Science Conference. *Annals of Internal Medicine* 2006;**145**(5):372–85.

**Johnson 2007**

Johnson AR, Munoz A, Gottlieb JL, Jarrard DF. High dose zinc increases hospital admissions due to genitourinary complications. *Journal of Urology* 2007;**177**(2):639–43.

**Klein 1993**

Klein R, Klein BEK, Linton KL, DeMets DL. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking. *American Journal of Epidemiology* 1993;**137**:190–200.

**Omenn 1996**

Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *New England Journal of Medicine* 1996;**334**(18):1189–90.

**Owen 2012**

Owen Christopher G, Jarrar Zakariya, Wormald Richard, Cook Derek G, Fletcher Astrid E, Rudnicka Alicja R. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. *British Journal of Ophthalmology* 2012;**96**(5):752–6.

**Review Manager 2011 [Computer program]**

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.

**References to other published versions of this review****Evans 1999**

Evans JR, Henshaw K. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. *Cochrane Database of Systematic Reviews* 1994, Issue 4. [DOI: 10.1002/14651858.CD000253]

**Evans 2008**

Evans JR, Henshaw KS. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. *Cochrane Database of Systematic Reviews* 2008, Issue 1. [DOI: 10.1002/14651858.CD000253.pub2]

\* Indicates the major publication for the study

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

#### ATBC

Methods	Method of allocation: random. Sponsor provided coded capsules. Masking: participant: yes; provider: yes; outcome: yes Exclusions after randomisation: no Losses to follow-up: 31%. Random sample for maculopathy study: 9%. Unusual study design: 2 x 2 factorial design. Maculopathy add-on random sample in 2 regions
Participants	Country: Finland Number of participants randomised: 29,133. Random sample of 1035 selected for maculopathy study. Age: 50 to 69 years in 1984. Maculopathy study 1992/3 in people aged 65 plus. Sex: Male Inclusion criteria: 5 or more cigarettes daily Exclusion criteria: history of cancer or serious disease limiting ability to participate; those taking supplements vitamin E, A or beta-carotene in excess of predefined doses; those treated with anticoagulants
Interventions	Treatment: 3 regimens: alpha-tocopherol (50 mg), beta-carotene (20 mg) or alpha-tocopherol and beta-carotene Control: placebo Duration: 5 to 8 years (median 6.1)
Outcomes	AMD: 4 grades: Grade I: dry maculopathy with hard drusen and/or pigmentary changes Grade II: soft macular drusen Grade III: disciform degeneration Grade IV: geographic atrophy
Notes	Compliance with treatment excellent; 4/5 active participants took more than 95% of scheduled capsules. Drop-out rate and compliance similar between all 4 groups

#### *Risk of bias*

#### *Risk of bias*

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	<i>"The participants were randomly assigned to one of four treatment groups: AT alone, AT and BC, BC alone, or placebo in a complete 2 x 2 factorial design"</i> and <i>"Randomization was performed in blocks of eight within each of the study areas."</i> The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant



ATBC (Continued)

		characteristics, and compliance. <i>Annals of Epidemiology</i> 1994;4: page 1
Allocation concealment (selection bias)	Low risk	“A coded reserve supply of capsule packs...” page 3 Not clearly stated that allocation concealed but the study was described as being “double-blind”
Blinding of participants and personnel (performance bias) AMD	Low risk	“The retinal specialist [...] examined six photographs (three per eye) of each participant without knowledge of the subject’s treatment group” Teikari et al page 226
Blinding of outcome assessment (detection bias) AMD	Low risk	“The retinal specialist [...] examined six photographs (three per eye) of each participant without knowledge of the subject’s treatment group” Teikari et al page 226
Incomplete outcome data (attrition bias) All outcomes	Low risk	“A total of 941 persons participated (91%) and non-participation rates were similar across the intervention groups.” Teikari et al page 226
Selective reporting (reporting bias)	Unclear risk	Visual acuity measured but not reported but as the main results for AMD showed no difference between groups it is not clear whether this is an example of selective reporting or whether in fact the investigators considered that visual acuity in this age group might be attributed to a variety of causes and therefore was not a relevant outcome

PHS I

Methods	Method of allocation: coded tablets Masking: participant: yes; provider: yes; outcome: yes 99% follow-up Unusual study design: 2 x 2 factorial design.
Participants	Country: USA Number randomised: originally 22,071 men were randomised: 11,036 to beta-carotene, 11,035 to beta-carotene placebo 21,142 participants were followed up for at least 7 years and provided information on diagnoses of AMD made during the first 7 years of the trial 10,585 were in the beta-carotene group and 10,557 were in the placebo group Age: 40 to 84 years in 1982 Sex: male

PHS I (Continued)

	<p>Inclusion criteria: Physician aged 40 to 84 years in 1982 with no history of cancer, myocardial infarction, stroke or transient cerebral ischaemia</p> <p>Exclusion criteria: personal history of cardiovascular disease or cancer; contraindications or current use of study medication;</p>
Interventions	<p>Treatment: 4 groups: 1. Aspirin 325 mg every other day plus beta-carotene placebo 2. Beta-carotene 50 mg every other day plus aspirin placebo 3. Both active agents</p> <p>Control: 4. Both placebos</p> <p>Duration: Aspirin component terminated early January 1988 Beta-carotene component terminated December 1995. Mean duration 12 years range (11.6 to 14.2 years)</p>
Outcomes	<p>Self report of AMD followed by medical record review and questionnaire to relevant ophthalmologist</p> <p>Primary endpoint: visually significant AMD, defined as a self report confirmed by medical record evidence of an initial diagnosis after randomisation but before 31 December 1995 with a reduction in best-corrected visual acuity to 20/30 or worse attributable to AMD</p> <p>Secondary endpoints: AMD with or without vision loss, composed of all incidence cases</p> <p>Advanced AMD, encompassed of cases of visually significant AMD with pathological signs of disciform scar, RPE detachment, geographic atrophy or subretinal neovascular membrane</p>
Notes	

<i>Risk of bias</i>		<i>Risk of bias</i>
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	<p>"The PHS I was a randomized, double-masked, placebo controlled trial..." Page 334 Christen et al 2007</p> <p>"A total of 22,071 physicians were then randomized according to a two-by-two factorial design, with use of a computer-generated list of random numbers..." Page 262 <i>New England Journal of Medicine</i> 1982</p>
Allocation concealment (selection bias)	Low risk	<p>"The PHS I was a randomized, double-masked, placebo controlled trial..." Page 334 Christen et al 2007</p>

PHS I (Continued)

Blinding of participants and personnel (performance bias) AMD	Low risk	<p><i>"The PHS I was a randomized, double-masked, placebo controlled trial..."</i> Page 334 Christen et al 2007</p> <p>Although this aspect of the trial was not well described the placebo control was described (placebo and supplement identical appearance and packaging) and the study was described as double-blind</p>
Blinding of outcome assessment (detection bias) AMD	Low risk	<p><i>"The PHS I was a randomized, double-masked, placebo controlled trial..."</i> Page 334 Christen et al 2007</p> <p>Although this aspect of the trial was not well described the placebo control was described and the study was described as double-blind. Diagnosis of AMD by self report based on health questionnaire (confirmed by ophthalmologist and optometrist). Patients and researchers unaware of intervention</p>
Incomplete outcome data (attrition bias) All outcomes	Low risk	<p><i>"At the end of 11 years of follow-up (the last year completed for all participants), 99.2% were still providing information on morbidity, and the follow-up for mortality was 99.9% complete. Eighty percent of participants in the beta carotene group and in the placebo group were still taking the study pills, with a mean compliance among pill takers of more than 97%. Therefore, even after 11 years, 78% of the study pills assigned in the beta carotene group were reported as still being taken. In the placebo group, 6% of participants reported taking supplemental beta carotene or vitamin A."</i> Christen et al 2007 page 334</p>
Selective reporting (reporting bias)	Low risk	Reported AMD outcomes as expected

VECAT

Methods	<p>Method of allocation: coded bottles</p> <p>Masking: participant: yes; provider: yes; outcome: yes</p> <p>Losses to follow-up: not known</p>
Participants	<p>Country: Australia</p> <p>Number of participants randomised: 1204</p> <p>Age: 55 to 80 years, mean 66</p>

VECAT (Continued)

	Sex: 56% female Inclusion criteria: lens and retina of at least one eye available for documentation Exclusion criteria: previous cataract surgery or advanced cataract in both eyes; steroid or anticoagulation use; serious disease; regular use or sensitivity to vitamin E
Interventions	Vitamin E 500 IU per day: natural vitamin E in soybean oil medium Control: placebo identical in sight, taste and smell Duration: 4 years
Outcomes	2 m logMAR visual acuity; clinical examination; colour stereoscopic fundus photographs graded using International Grading Scheme
Notes	Worse eye used as the study eye Methodology published but results available from abstract only

<i>Risk of bias</i>		<i>Risk of bias</i>
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	<i>"This random allocation was performed by using a "permuted blocks" allocation scheme"</i> Page 2
Allocation concealment (selection bias)	Low risk	<i>"Study numbers were allocated sequentially by the study coordinator as participants were enrolled in the study. Participants were then randomly allocated to treatment group. The allocation list was stored at a remote site."</i> Page 2
Blinding of participants and personnel (performance bias) Visual acuity	Low risk	<i>"Participants randomly received either 500 IU natural vitamin E (335 mg dá tocopherol) in a soybean oil suspension encapsulated in gelatin or a matched placebo capsule containing only the soybean oil." [...] "Bulk medications were dispensed into labelled jars by a person not involved in the study. Vitamin E and placebo were dispensed on different days to avoid confusion. Identical containers were used. The jars were packed in numerical order and then dispensed by study personnel. Vitamin E and placebo capsules were of identical appearance and taste. Neither study staff nor examiners or participants were aware of the treatment allocation, although all knew that participants would be randomly assigned to receive either vitamin E or placebo."</i> Page 2

<p>Blinding of participants and personnel (performance bias) AMD</p>	<p>Low risk</p>	<p><i>“Participants randomly received either 500 IU natural vitamin E (335 mg d<math>\alpha</math>-tocopherol) in a soybean oil suspension encapsulated in gelatin or a matched placebo capsule containing only the soybean oil.” [...] “Bulk medications were dispensed into labelled jars by a person not involved in the study. Vitamin E and placebo were dispensed on different days to avoid confusion. Identical containers were used. The jars were packed in numerical order and then dispensed by study personnel. Vitamin E and placebo capsules were of identical appearance and taste. Neither study staff nor examiners or participants were aware of the treatment allocation, although all knew that participants would be randomly assigned to receive either vitamin E or placebo.” Page 2</i></p>
<p>Blinding of outcome assessment (detection bias) Visual acuity</p>	<p>Low risk</p>	<p><i>“Neither study staff nor examiners or participants were aware of the treatment allocation, although all knew that participants would be randomly assigned to receive either vitamin E or placebo.” Page 2</i></p>
<p>Blinding of outcome assessment (detection bias) AMD</p>	<p>Low risk</p>	<p><i>“Neither study staff nor examiners or participants were aware of the treatment allocation, although all knew that participants would be randomly assigned to receive either vitamin E or placebo.” Page 2</i> <i>“At the end of the study we reassessed the initial and final photographs for any change with a “side by side” comparison in a masked and randomised fashion”. Page 2</i></p>
<p>Incomplete outcome data (attrition bias) All outcomes</p>	<p>Low risk</p>	<p><i>“From the 1906 people who were screened by telephone, 1289 (69%) were examined and 1204 (93%) of these were enrolled and randomised. We excluded 11 participants after randomisation as they were outside the required age range at enrolment.” Page 1</i> <i>“In the vitamin E group eight people were excluded from final data analysis: six developed diabetic retinopathy, one had myopic degeneration, and one had missing data. Six people were excluded from the placebo group: two developed adult vitelliform macular degeneration and four had</i></p>

VECAT (Continued)

		<p><i>missing data</i>" Page 3            Figure 3 Page 4 1204 randomised, 11 excluded after randomisation, 14 excluded from analysis 8/595 vitamin E group and 6/598 placebo group</p>
Selective reporting (reporting bias)	Low risk	<p>AMD incidence and progression reported but no difference between groups; visual acuity not reported but "<i>Analysis of best corrected visual acuity and visual function data showed no differences between the groups (data not shown).</i>" Page 4. Therefore no evidence that outcomes with "better" results selectively reported</p>

WHS

Methods	<p>Method of allocation:            Masking: participant: yes; provider: yes; outcome: yes            Losses to follow-up: not known</p>
Participants	<p>Country: USA            Number of participants randomised: 39,876 women health professionals            Age: 45+            Sex: 100% female            Inclusion/exclusion criteria:            a) Female; (b) aged 45 years or older; (c) postmenopausal or with no intention of becoming pregnant; (d) no reported personal history of cardiovascular disease, cancer (other than non-melanoma skin cancer), gout, peptic ulcer, chronic renal or liver disease, or other serious illness precluding participation; (e) no reported history of serious side effects to the study treatments; (f) not currently taking aspirin, aspirin containing medication, or nonsteroidal anti-inflammatory drugs (NSAIDs) more than 1 day per week or, if so doing, willing to forego use of these medications; (g) not currently taking individual supplements of vitamin E or beta-carotene more than 1 day per week; (h) not currently taking anticoagulants or corticosteroids</p>
Interventions	Vitamin E (600 IU on alternate days) or placebo
Outcomes	Self report and review of medical records
Notes	NCT00000161

<i>Risk of bias</i>		<i>Risk of bias</i>
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>

WHS (Continued)

Random sequence generation (selection bias)	Low risk	<i>"The WHS was a randomized, double-blind, placebo-controlled, 2x2 factorial trial. ."</i> Page 1163
Allocation concealment (selection bias)	Low risk	<i>"The WHS was a randomized, double-blind, placebo-controlled, 2x2 factorial trial. ."</i> Page 1163
Blinding of participants and personnel (performance bias) Visual acuity	Low risk	<i>"Study medications and end-point ascertainment were continued in a blinded fashion through the scheduled end of the trial (March 31, 2004)." Ridker et al 2005 page 1294 "Pill taking and end point ascertainment were continued in blinded fashion through the scheduled end of the trial on March 31, 2004. Morbidity and mortality follow-up were 97.2% and 99.4% complete, respectively." Page 1164</i>
Blinding of participants and personnel (performance bias) AMD	Low risk	<i>"Study medications and end-point ascertainment were continued in a blinded fashion through the scheduled end of the trial (March 31, 2004)." Ridker et al 2005 page 1294 "Pill taking and end point ascertainment were continued in blinded fashion through the scheduled end of the trial on March 31, 2004. Morbidity and mortality follow-up were 97.2% and 99.4% complete, respectively." Page 1164</i>
Blinding of outcome assessment (detection bias) Visual acuity	Low risk	<i>"Study medications and end-point ascertainment were continued in a blinded fashion through the scheduled end of the trial (March 31, 2004)." Ridker et al 2005 page 1294 "Pill taking and end point ascertainment were continued in blinded fashion through the scheduled end of the trial on March 31, 2004. Morbidity and mortality follow-up were 97.2% and 99.4% complete, respectively." Page 1164</i>
Blinding of outcome assessment (detection bias) AMD	Low risk	<i>"Study medications and end-point ascertainment were continued in a blinded fashion through the scheduled end of the trial (March 31, 2004)." Ridker et al 2005 page 1294 "Pill taking and end point ascertainment were continued in blinded fashion through the scheduled end of the trial on March 31, 2004. Morbidity and mortality follow-up were 97.2% and 99.4% complete, respectively." Page 1164</i>

		2% and 99.4% complete, respectively.” Page 1164
Incomplete outcome data (attrition bias) All outcomes	Low risk	<p>“Compliance (defined as taking at least two thirds of the study capsules) was 78.9% at 5 years and 71.6% at 10 years, and averaged 75.8% throughout the trial.” Page 1164</p> <p>“Pill taking and end point ascertainment were continued in blinded fashion through the scheduled end of the trial on March 31, 2004. Morbidity and mortality follow-up were 97.2% and 99.4% complete, respectively.” Page 1164</p> <p>Follow-up balanced across treatment groups. See figure 1 page 1164</p>
Selective reporting (reporting bias)	Low risk	No evidence of selective reporting. The outcome was limited to the study design - medical record review. Primary and secondary outcomes were apparently defined a priori and were reported

AMD: age-related macular degeneration  
 ETDRS: Early Treatment Diabetic Retinopathy Study  
 IU: international units  
 RPE: retinal pigment epithelium

**Characteristics of excluded studies [ordered by study ID]**

Study	Reason for exclusion
ADSC	No published data on age-related macular degeneration. No response from author
Andrews 1969	No published data on age-related macular degeneration. Unable to contact author
AREDS	Age-related maculopathy outcomes for people without age-related maculopathy at baseline were not reported
Benner 1994	No published data on age-related macular degeneration. No response from author
Benton 1995	No data on age-related macular degeneration collected
Blok 1997	No data on age-related macular degeneration collected



(Continued)

Bogden 1990	No published data on age-related macular degeneration. No response from author
Bone 2010	Biological availability study only
Brewer 1997	No published data on age-related macular degeneration. No response from author
Brown 1998	No published data on age-related macular degeneration. No response from author
Bussey 1982	No published data on age-related macular degeneration. No response from author
Caligiuri 1997	No published data on age-related macular degeneration. No response from author
CARET	No data on age-related macular degeneration collected
CARMIS	Study on people with AMD (non-advanced AMD) therefore not on prevention in healthy people
CCSG	No published data on age-related macular degeneration. No response from author
Chandra 1992	No published data on age-related macular degeneration. No response from author
CHAOS	No data on age-related macular degeneration collected
Clausen 1989	No published data on age-related macular degeneration. No response from author
Constans 1996	No published data on age-related macular degeneration. No response from author
Constantino 1988	No data on age-related macular degeneration collected
Cucinotta 1994	No published data on age-related macular degeneration. No response from author
DATATOP	No published data on age-related macular degeneration. Unable to contact author
de Klerk 1998	No data on age-related macular degeneration collected
DeCosse 1989	No published data on age-related macular degeneration. No response from author
Dobson 1984	No data on age-related macular degeneration collected
ECP-IM	No published data on age-related macular degeneration. No response from author
EUROSCAN	No published data on age-related macular degeneration. No response from author
Fairley 1996	No published data on age-related macular degeneration. No response from author
Falsani 2010	Participants had early AMD

(Continued)

Fontham 1995	No data on age-related macular degeneration collected
Galan 1997	No published data on age-related macular degeneration. No response from author
Garawal 1995	No published data on age-related macular degeneration. No response from author
GISSI	No published data on age-related macular degeneration. No response from author
HOPE	No data on age-related macular degeneration collected
Johnson 1997	No published data on age-related macular degeneration. No response from author
Jyothirmayi 1996	No published data on age-related macular degeneration. No response from author
Kuklinski 1994	No published data on age-related macular degeneration. No response from author
Kvansakul 2006	No AMD outcomes
Leng 1997	No published data on age-related macular degeneration. Unable to contact author
Li 1992	No published data on age-related macular degeneration. No response from author
LINXIAN	No published data on age-related macular degeneration. No response from author
Mayne 1998	No data on age-related macular degeneration collected
McKeown 1988	No data on age-related macular degeneration collected
Meyskens 1994	No published data on age-related macular degeneration. No response from author
Munoz 1987	No published data on age-related macular degeneration. No response from author
Munoz 1996	No published data on age-related macular degeneration. No response from author
Nambour 1995	No follow-up data on age-related macular degeneration collected
NCT00718653	Study of macular pigment only
NCT01208948	No AMD outcomes
Newsome, 2008	Study on people with AMD
NPCSG	No published data on age-related macular degeneration. No response from author
Pastorino 1991	No published data on age-related macular degeneration. No response from author
Pemp 2010	Study of ocular blood flow and endothelial function only in model of oxidative stress in health volunteers

(Continued)

Peng 1993	No published data on age-related macular degeneration. No response from author
PPP	No published data on age-related macular degeneration. No response from author
PPSG	No data on age-related macular degeneration collected
Prasad 1995	No published data on age-related macular degeneration. No response from author
REACT	No published data on age-related macular degeneration. No response from author
Recchia 1995	No published data on age-related macular degeneration. No response from author
Rein 2007	Study not a randomised controlled trial
Ret Pig 1993	No published data on age-related macular degeneration. No response from author
Rodriguez-Carmona 2006	No AMD outcomes
SAINTS	Study on people with AMD
SCPS 1989	No data on age-related macular degeneration collected
SECURE	No published data on age-related macular degeneration. No response from author
Shandong 1998	No data on age-related macular degeneration collected
Sharma 1989	No published data on age-related macular degeneration. No response from author
Steiner 1995	No published data on age-related macular degeneration. No response from author
SUVIMAX	No published data on age-related macular degeneration. No response from author
SWSCPSG	No data on age-related macular degeneration collected
Takamatsu 1995	No published data on age-related macular degeneration. No response from author
Tomeo 1995	No published data on age-related macular degeneration. No response from author
Tsubono 1997	No data on age-related macular degeneration collected
WAFACS	Reported on folic acid, pyridoxine and cyanocobalamin combination treatment
Wahlqvist 1994	No data on age-related macular degeneration collected
Wong 2010	Participants had geographic atrophy

(Continued)

Wright 1985	No published data on age-related macular degeneration. No response from author
Yu 1991	No published data on age-related macular degeneration. No response from author
YUNNAN	No published data on age-related macular degeneration. No response from author
Zaridze 1993	No published data on age-related macular degeneration. No response from author

AMD: age-related macular degeneration

### Characteristics of ongoing studies [ordered by study ID]

#### AREDS2

Trial name or title	Age-Related Eye Disease Study 2 (AREDS2): a multi-center, randomized trial of lutein, zeaxanthin and omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) in age-related macular degeneration
Methods	AREDS2 is a multi-centre randomised trial of approximately 4200 participants, designed to assess the effects of oral supplementation of high doses of macular xanthophylls (lutein and zeaxanthin) and omega-3 LCPUFAs (DHA and EPA) for the treatment of AMD and cataract. AREDS2 was designed to evaluate the effects of high supplemental doses of lutein and zeaxanthin and omega-3 LCPUFAs on the development of advanced AMD. The study enrolled participants aged 50 to 85 years, with sufficiently clear ocular media to allow accurate assessment of AMD from fundus photographs. All participants are offered additional treatment with the original AREDS formulation (now considered standard of care) and 3 variations of this formula. These are: (1) no beta-carotene; (2) lower amounts of zinc; and (3) no beta-carotene and lower amounts of zinc. Eligible participants are followed for a minimum of 5 years
Participants	Participants were enrolled on the basis of the AREDS Simplified Severity Scale for defining risk categories for development of advanced age-related macular degeneration
Interventions	10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules) Factorial design, 3 arms (no arm with placebo for both)
Outcomes	Primary outcome measures: Progression to advanced AMD in people at moderate to high risk for progression Secondary outcome measures: Progression to moderate vision loss Adverse events Progression of lens opacity or incidence of cataract surgery Effect of study supplements on cognitive function Effect of DHA/EPA on cardiovascular morbidity and mortality
Starting date	2006

**AREDS2** (Continued)

Contact information	See: <a href="http://clinicaltrials.gov/show/NCT00345176">http://clinicaltrials.gov/show/NCT00345176</a>
Notes	-

**LIMPIA**

Trial name or title	Lutein influence on macula of persons issued from AMD parents
Methods	Multicentre, double-masked, randomised clinical trial of supplementation with 'Nutrof Total' (lutein and zeaxanthin) versus placebo
Participants	People at high genetic risk for AMD because their parents had AMD. Age 40 to 70 years
Interventions	Nutrof Total or placebo
Outcomes	Primary outcome measure: Macular pigment density at 6 months after supplementation Secondary outcome measures: Best corrected visual acuity 12 months Cognitive ability 12 months Plasma fatty acids 12 months Macular pigment density during supplementation and after stopping supplementation
Starting date	-
Contact information	Jean-Francois Korobelnik jean-francois.korobelnik@chu-bordeaux.fr
Notes	<a href="http://clinicaltrials.gov/show/NCT01269697">http://clinicaltrials.gov/show/NCT01269697</a>

**PHS II**

Trial name or title	Physician's Health Study II
Methods	Randomised controlled trial
Participants	15,000 physicians aged 55 or older
Interventions	2 x 2 x 2 x 2 factorial design Alternate day beta-carotene, alternate day vitamin E, daily vitamin C and a daily multivitamin
Outcomes	Age-related macular degeneration: reported diagnosis followed up by contact with treating ophthalmologist/optometrist
Starting date	-
Contact information	-

**PHS II** (Continued)

Notes	-
-------	---

**SELECT**

Trial name or title	Selenium and Vitamin E Cancer Prevention Trial (SELECT) for prostate cancer
Methods	This is a randomised, double-masked, multi-centre study. Participants are randomised to one of 4 prevention arms: Arm I: participants receive 2 different oral placebos once daily Arm II: participants receive oral selenium and oral placebo once daily Arm III: participants receive oral vitamin E and oral placebo once daily Arm IV: participants receive oral selenium and oral vitamin E once daily Treatment continues for 7 to 12 years in the absence of unacceptable toxicity or diagnosis of prostate cancer Quality of life is assessed at baseline and then at 1, 3, 5 and 7 years Participants are followed annually
Participants	Healthy male volunteers. A total of 32,400 participants (8100 per prevention arm) will be accrued for this study within 5 years
Interventions	Dietary supplement: selenium Dietary supplement: vitamin E
Outcomes	Primary outcome measures: Effect on the clinical incidence of cancer Effect on cancer-free survival, overall survival and serious cardiovascular events Quality of life Association of biological molecular markers with cancer risk Relationship between effects on cancer risk and genetic factors Effects in terms of intake of other nutrients, foods and dietary supplements Effect of other dietary nutrients and dietary patterns on cancer risk Effects on the reduction of Alzheimer's disease incidence Reduction in the risk of age-related macular degeneration or cataract
Starting date	July 2001
Contact information	-
Notes	<a href="http://clinicaltrials.gov/show/NCT00006392">http://clinicaltrials.gov/show/NCT00006392</a>

**WACS**

Trial name or title	Women's Antioxidant Cardiovascular Study
Methods	-
Participants	8171 female health professionals aged 40 plus with pre-existing cardiovascular disease (CVD) or high risk for developing CVD

**WACS** (Continued)

Interventions	2 x 2 x 2 x 2 factorial design: Vitamin E (600 IU on alternate days) Vitamin C (500 mg daily) Beta-carotene (5 mg on alternate days) Combination of folate (800 mg daily), vitamin B6 (25 mg daily) and vitamin B12 (1 mg daily)
Outcomes	Self report and review of medical records
Starting date	1993
Contact information	-
Notes	<a href="http://clinicaltrials.gov/show/NCT00000541">http://clinicaltrials.gov/show/NCT00000541</a>

AMD: age-related macular degeneration

## DATA AND ANALYSES

### Comparison 1. Any antioxidant versus placebo

---

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 AMD	4	62520	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.89, 1.08]
2 Advanced AMD	4	62520	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.80, 1.39]

### Comparison 2. Alpha-tocopherol versus placebo

---

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 AMD	3	40887	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.85, 1.09]
2 Advanced AMD	3	40887	Risk Ratio (M-H, Fixed, 95% CI)	1.34 [0.84, 2.14]

### Comparison 3. Beta-carotene versus placebo

---

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 AMD	2	21589	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.89, 1.19]
2 Advanced AMD	2	21589	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.69, 1.36]




### Analysis 1.1. Comparison 1 Any antioxidant versus placebo, Outcome 1 AMD.

Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration

Comparison: 1 Any antioxidant versus placebo

Outcome: 1 AMD




## Analysis 1.2. Comparison 1 Any antioxidant versus placebo, Outcome 2 Advanced AMD.

Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration

Comparison: 1 Any antioxidant versus placebo

Outcome: 2 Advanced AMD




### Analysis 2.1. Comparison 2 Alpha-tocopherol versus placebo, Outcome 1 AMD.

Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration

Comparison: 2 Alpha-tocopherol versus placebo

Outcome: 1 AMD




### Analysis 2.2. Comparison 2 Alpha-tocopherol versus placebo, Outcome 2 Advanced AMD.

Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration

Comparison: 2 Alpha-tocopherol versus placebo

Outcome: 2 Advanced AMD




### Analysis 3.1. Comparison 3 Beta-carotene versus placebo, Outcome 1 AMD.

Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration

Comparison: 3 Beta-carotene versus placebo

Outcome: 1 AMD




### Analysis 3.2. Comparison 3 Beta-carotene versus placebo, Outcome 2 Advanced AMD.

Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration

Comparison: 3 Beta-carotene versus placebo

Outcome: 2 Advanced AMD



## APPENDICES

### Appendix I. CENTRAL search strategy

- #1 MeSH descriptor Macular Degeneration
- #2 MeSH descriptor Retinal Degeneration
- #3 MeSH descriptor Retinal Neovascularization
- #4 MeSH descriptor Choroidal Neovascularization
- #5 MeSH descriptor Macula Lutea
- #6 macula\* near lutea\*
- #7 (macula\* or retina\* or choroid\*) near/4 degenerat\*
- #8 (macula\* or retina\* or choroid\*) near/4 neovascul\*
- #9 maculopath\*
- #10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
- #11 MeSH descriptor Vitamins
- #12 vitamin\*
- #13 MeSH descriptor Vitamin A
- #14 retinol\*
- #15 MeSH descriptor beta Carotene
- #16 caroten\*
- #17 MeSH descriptor Ascorbic Acid
- #18 ascorbic next acid
- #19 MeSH descriptor Vitamin E
- #20 MeSH descriptor alpha-Tocopherol

#21 alpha tocopherol\*  
 #22 MeSH descriptor Vitamin B 12  
 #23 cobalamin\*  
 #24 MeSH descriptor Antioxidants  
 #25 antioxidant\* or anti oxidant\*  
 #26 MeSH descriptor Carotenoids  
 #27 carotenoid\*  
 #28 MeSH descriptor Zinc  
 #29 zinc\*  
 #30 MeSH descriptor Riboflavin  
 #31 riboflavin\*  
 #32 MeSH descriptor Selenium  
 #33 selenium\*  
 #34 MeSH descriptor Lutein  
 #35 lutein\*  
 #36 MeSH descriptor Xanthophylls  
 #37 xanthophyll\*  
 #38 zeaxanthin\*  
 #39 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)  
 #40 (#25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38)  
 #41 (#39 OR #40)  
 #42 (#10 AND #41)

## Appendix 2. MEDLINE (OvidSP) search strategy

1. exp clinical trial/ [publication type]
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp macular degeneration/
14. exp retinal degeneration/
15. exp retinal neovascularization/
16. exp choroidal neovascularization/
17. exp macula lutea/
18. maculopath\$.tw.
19. ((macul\$ or retina\$ or choroid\$) adj3 degener\$).tw.
20. ((macul\$ or retina\$ or choroid\$) adj3 neovasc\$).tw.
21. (macula\$ adj2 lutea).tw.
22. or/13-21
23. exp vitamins/
24. exp vitamin A/
25. vitamin A.tw.
26. retinol\$.tw.
27. exp beta carotene/

28. caroten\$.tw.
29. exp ascorbic acid/
30. ascorbic acid\$.tw.
31. vitamin C.tw.
32. exp Vitamin E/
33. exp alpha tocopherol/
34. alpha?tocopherol\$.tw.
35. alpha tocopherol\$.tw.
36. vitamin E.tw.
37. exp Vitamin B12/
38. vitamin B12.tw.
39. cobalamin\$.tw.
40. exp antioxidants/
41. ((antioxidant\$ or anti) adj1 oxidant\$).tw.
42. exp carotenoids/
43. carotenoid\$.tw.
44. exp zinc/
45. zinc\$.tw.
46. exp riboflavin/
47. riboflavin\$.tw.
48. exp selenium/
49. selenium\$.tw.
50. exp lutein/
51. lutein\$.tw.
52. exp xanthophylls/
53. xanthophyll.tw.
54. zeaxanthin\$.tw.
55. or/23-54
56. 22 and 55
57. 12 and 56

The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville ([Glanville 2006](#)).

### Appendix 3. EMBASE (OvidSP) search strategy

1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random\$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin\$ adj3 trial\$).tw.
14. ((singl\$ or doubl\$ or trebl\$ or tripl\$) adj3 (blind\$ or mask\$)).tw.
15. exp placebo/
16. placebo\$.tw.
17. random\$.tw.
18. exp experimental design/

19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control\$ or prospectiv\$ or volunteer\$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula degeneration/
34. exp retina degeneration/
35. exp retina neovascularization/
36. exp subretinal neovascularization/
37. maculopath\$.tw.
38. ((macul\$ or retina\$ or choroid\$) adj3 degener\$).tw.
39. ((macul\$ or retina\$ or choroid\$) adj3 neovasc\$).tw.
40. exp retina macula lutea/
41. (macula\$ adj2 lutea\$).tw.
42. or/33-41
43. exp vitamins/
44. exp Retinol/
45. vitamin A.tw.
46. retinol\$.tw.
47. exp beta carotene/
48. caroten\$.tw.
49. exp ascorbic acid/
50. ascorbic acid\$.tw.
51. vitamin C.tw.
52. exp alpha tocopherol/
53. alpha?tocopherol\$.tw.
54. alpha tocopherol\$.tw.
55. vitamin E.tw.
56. vitamin B12.tw.
57. exp cyanocobalamin/
58. cobalamin\$.tw.
59. exp antioxidants/
60. ((antioxidant\$ or anti) adj1 oxidant\$).tw.
61. exp carotenoid/
62. exp zinc/
63. zinc\$.tw.
64. exp riboflavin/
65. riboflavin\$.tw.
66. exp selenium/
67. selenium\$.tw.
68. exp zeaxanthin/
69. zeaxanthin\$.tw.
70. lutein\$.tw.
71. xanthophyll.tw.



72. or/43-71
73. 42 and 72
74. 32 and 73

#### **Appendix 4. AMED (OvidSP) search strategy**

1. exp eye disease/
2. exp vision disorders/
3. exp retinal disease/
4. maculopath\$.tw.
5. ((macul\$ or retina\$ or choroid\$) adj3 degenerat\$).tw.
6. ((macul\$ or retina\$ or choroid\$) adj3 neovasc\$).tw.
7. or/1-6
8. exp vitamins/
9. vitamin A.tw.
10. retinol\$.tw.
11. exp carotenoids/
12. caroten\$.tw.
13. exp ascorbic acid/
14. ascorbic acid\$.tw.
15. vitamin C.tw.
16. vitamin E.tw.
17. alpha tocopherol\$.tw.
18. vitamin B12.tw.
19. cobalamin\$.tw.
20. exp antioxidants/
21. ((antioxidant\$ or anti) adj1 oxidant\$).tw.
22. zinc/
23. zinc\$.tw.
24. riboflavin\$.tw.
25. selenium/
26. selenium\$.tw.
27. lutein\$.tw.
28. xanthophylls.tw.
29. zeaxanthin\$.tw.
30. or/8-29
31. 7 and 30

#### **Appendix 5. Open Grey search strategy**

macular degeneration AND antioxidant

## **Appendix 6. metaRegister of Controlled Trials search strategy**

(macular degeneration) AND (antioxidant or vitamin or carotene or selenium or tocopherol)

## **Appendix 7. ClinicalTrials.gov search strategy**

(Macular Degeneration) AND (Antioxidant OR Vitamin OR Carotene OR Selenium OR Tocopherol)

## **Appendix 8. ICTRP search strategy**

Macular Degeneration = Condition AND Antioxidant OR Vitamin OR Carotene OR Selenium OR Tocopherol = Intervention

## **Appendix 9. MEDLINE (OvidSP) adverse effects search strategy**

1. exp retinal degeneration/
2. retinal neovascularization/
3. choroidal neovascularization/
4. exp macula lutea/
5. (macula\$ adj2 lutea).tw.
6. ((macul\$ or retina\$ or choroid\$) adj4 degener\$).tw.
7. ((macul\$ or retina\$ or choroid\$) adj4 neovasc\$).tw.
8. (AMD or ARMD or CNV).tw.
9. maculopath\$.tw.
10. or/1-9
11. exp vitamins/
12. vitamin A.tw.
13. retinol\$.tw.
14. (caroten\$ or betacaroten\$).tw.
15. ascorbic acid\$.tw.
16. vitamin C.tw.
17. alpha?tocopherol\$.tw.
18. alpha tocopherol\$.tw.
19. vitamin E.tw.
20. ((antioxidant\$ or anti) adj1 oxidant\$).tw.
21. zinc/
22. zinc\$.tw.
23. or/11-22
24. 10 and 23
25. ae.fs.
26. 24 and 25
27. limit 26 to (meta analysis or randomized controlled trial or "review")

## WHAT'S NEW

Last assessed as up-to-date: 26 January 2012.

Date	Event	Description
19 April 2012	New search has been performed	Issue 6 2012: New searches yielded one new trial. New 'Risk of bias' grading and a 'Summary of findings' table have been included
19 April 2012	New citation required but conclusions have not changed	Issue 6 2012: The author byline has changed. Katherine Henshaw has been replaced by a new author, John Lawrenson

## HISTORY

Protocol first published: Issue 3, 1997

Review first published: Issue 4, 1999

Date	Event	Description
28 August 2008	Amended	Converted to new review format.
8 November 2007	New citation required and conclusions have changed	Substantive amendment. Issue 1 2008: The results for PHS I are included. AREDS was previously included in this review but as no numerical data were available from the study as regards prevention of AMD, it was excluded from the review. The results of AREDS are presented in the review 'Antioxidants for slowing down the progression of AMD'

## CONTRIBUTIONS OF AUTHORS

JE assessed studies for inclusion/exclusion, assessed risk of bias, extracted data, entered data and wrote the text of the review.

JL assessed studies for inclusion/exclusion, assessed risk of bias, extracted data, and reviewed and commented on the text of the review.

## DECLARATIONS OF INTEREST

None known.

## SOURCES OF SUPPORT

### Internal sources

- NIHR/Department of Health, UK.
- JE was funded by NIHR during the updating of this review (Issue 6, 2012)

### External sources

- No sources of support supplied

## INDEX TERMS

### Medical Subject Headings (MeSH)

\*Dietary Supplements; Antioxidants [\*administration & dosage]; Macular Degeneration [\*prevention & control]; Minerals [administration & dosage]; Randomized Controlled Trials as Topic; Vitamins [\*administration & dosage]; alpha-Tocopherol [administration & dosage]; beta Carotene [administration & dosage]

### MeSH check words

Humans